{"content":"<li class=\"n-box-item date-title\" data-end=\"1520913599\" data-start=\"1520827200\" data-txt=\"Monday, December 23, 2019\">Monday, March 12, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3338545\" data-ts=\"1520895137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTI\" target=\"_blank\">WTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338545-w-and-t-offshore-unveils-gulf-of-mexico-joint-exploration-development-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">W&amp;T Offshore unveils Gulf of Mexico joint exploration, development program</a></h4><ul>     <li>W&amp;T&nbsp;Offshore (NYSE:<a href='https://seekingalpha.com/symbol/WTI' title='W&T Offshore, Inc.'>WTI</a>)&nbsp;<font color='green'>+5.8%</font> after-hours as it enters into joint exploration and development agreements with an investor group to <a href=\"https://seekingalpha.com/pr/17099732-w-and-t-offshore-announces-gulf-mexico-joint-exploration-development-program-investor-group\" target=\"_blank\">drill as many as 14 specified projects </a>in the Gulf of Mexico over the next three years or more, with an initial capital commitment of $230M.</li>     <li>WTI says the total anticipated project level commitment is as much as $419.6M, including the company's own commitment; the initial capital commitment of $230.5M is subject to increase up to a maximum $275.9M commitment if additional investors join the drilling program.</li>     <li>The investor group initially will receive 70% of the net revenues from the group of wells for 80% of the total well costs, while W&amp;T initially will receive 30% of net revenues for 20% of the total well costs; once the investor group achieves certain return thresholds with respect to a given well, WTI would receive 38.4% of the net revenues attributable to the well.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338545\" data-linked=\"W&amp;T Offshore unveils Gulf of Mexico joint exploration, development program\" data-tweet=\"$WTI - W&amp;T Offshore unveils Gulf of Mexico joint exploration, development program https://seekingalpha.com/news/3338545-w-and-t-offshore-unveils-gulf-of-mexico-joint-exploration-development-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3338545-w-and-t-offshore-unveils-gulf-of-mexico-joint-exploration-development-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338544\" data-ts=\"1520894156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALT\" target=\"_blank\">ALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338544-altimmuneplus-16-after-data-from-anthrax-vaccine-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altimmune +16% after data from anthrax vaccine program</a></h4><ul>     <li>Altimmune (NASDAQ:<a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a>) <font color='green'>+16.6%</font> after-hours following release of <a href=\"https://globenewswire.com/news-release/2018/03/12/1420914/0/en/Altimmune-Announces-Pre-Clinical-Data-From-its-SparVax-L-Anthrax-Vaccine-Program.html\" target=\"_blank\">pre-clinical data</a> from its SparVax-L anthrax vaccine program.</li>     <li>ALT says data from the study showed a 67% survival  rate in animals challenged with a lethal dose of anthrax after a single dose of SparVax-L, which the company is developing through federal funding from the National Institute of Allergy and Infectious Diseases.</li>     <li>The study compared SparVax-L to BioThrax,  the currently approved vaccine against anthrax infection, and ALT says the 100% survival rate  after two doses of SparVax-L at day 0 and day 14&nbsp; was comparable to BioThrax&rsquo;s 96% survival rate after two doses.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338544\" data-linked=\"Altimmune +16% after data from anthrax vaccine program\" data-tweet=\"$ALT - Altimmune +16% after data from anthrax vaccine program https://seekingalpha.com/news/3338544-altimmuneplus-16-after-data-from-anthrax-vaccine-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3338544-altimmuneplus-16-after-data-from-anthrax-vaccine-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338542\" data-ts=\"1520893777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KURA\" target=\"_blank\">KURA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338542-kura-oncologyminus-11_8-after-earnings-regulatory-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kura Oncology -11.8% after earnings, regulatory update</a></h4><ul>   <li>Along with a mostly in-line <a href=\"https://seekingalpha.com/news/3338469-kura-oncology-misses-0_01\" target=\"_blank\">earnings report for Q4</a>, Kura Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/KURA' title='Kura Oncology'>KURA</a>) has issued a <a href=\"https://seekingalpha.com/pr/17099566-kura-oncology-provides-regulatory-update-tipifarnib-reports-fourth-quarter-full-year-2017\" target=\"_blank\">regulatory update</a> on tipifarnib, its lead product candidate.</li>    <li>The company's shares are <font color='red'>down 11.8%</font> postmarket.</li>    <li>It's setting the second half of the year for a single-arm, registration-directed trial of tipifarnib in at least 59 patients (recurrent or metastatic) with HRAS mutant squamous cell head and neck cancer, with objective response rate as the primary endpoint.</li>    <li>\"We are encouraged by the feedback we received from the FDA regarding the development path for tipifarnib in HRAS mutant HNSCC, and we look forward to providing more specific information regarding the design and execution of the trial in the months ahead,\" CEO Troy Wilson says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338542\" data-linked=\"Kura Oncology -11.8% after earnings, regulatory update\" data-tweet=\"$KURA - Kura Oncology -11.8% after earnings, regulatory update https://seekingalpha.com/news/3338542-kura-oncologyminus-11_8-after-earnings-regulatory-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3338542-kura-oncologyminus-11_8-after-earnings-regulatory-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338541\" data-ts=\"1520893440\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AQUA\" target=\"_blank\">AQUA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338541-evoqua-waterminus-2_7-on-17_5m-share-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evoqua Water -2.7% on 17.5M-share secondary offering</a></h4><ul>   <li>Evoqua Water Technologies (NYSE:<a href='https://seekingalpha.com/symbol/AQUA' title='Evoqua Water Technologies Corp.'>AQUA</a>) is <font color='red'>2.7% lower</font> postmarket after a <a href=\"https://seekingalpha.com/filing/3932910\" target=\"_blank\">filing notes</a> a secondary public offering of 17.5M shares.</li>    <li>The shares are being sold by affiliates of AEA Investors; the company isn't selling any shares in the offering and won't see any proceeds.</li>    <li>In connection with the deal, AEA will grant underwriters a 30-day greenshoe option to buy up to 2.625M additional shares at the offering price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338541\" data-linked=\"Evoqua Water -2.7% on 17.5M-share secondary offering\" data-tweet=\"$AQUA - Evoqua Water -2.7% on 17.5M-share secondary offering https://seekingalpha.com/news/3338541-evoqua-waterminus-2_7-on-17_5m-share-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3338541-evoqua-waterminus-2_7-on-17_5m-share-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338536\" data-ts=\"1520891421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYGN\" target=\"_blank\">MYGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338536-myriad-geneticsminus-6-after-disclosing-u-s-government-billing-probe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myriad Genetics -6% after disclosing U.S. government billing probe</a></h4><ul>     <li>Myriad Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/MYGN' title='Myriad Genetics, Inc.'>MYGN</a>) <font color='red'>-6.6%</font> after-hours as it discloses that <a href=\"https://www.sec.gov/Archives/edgar/data/899923/000119312518079378/d550399d8k.htm\" target=\"_blank\">received a subpoena</a> from the U.S. Department of Health and Human Services related to an investigation into possible false and improper claims submitted for payment under Medicare and Medicaid.</li>     <li>MYGN says the subpoena requested documents dating back to January 2014 related primarily to billing to government-funded healthcare programs for its hereditary cancer testing; the company says it is cooperating with the government's request.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3338536\" data-linked=\"Myriad Genetics -6% after disclosing U.S. government billing probe\" data-tweet=\"$MYGN - Myriad Genetics -6% after disclosing U.S. government billing probe https://seekingalpha.com/news/3338536-myriad-geneticsminus-6-after-disclosing-u-s-government-billing-probe?source=tweet\" data-url=\"https://seekingalpha.com/news/3338536-myriad-geneticsminus-6-after-disclosing-u-s-government-billing-probe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338533\" data-ts=\"1520890708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338533-after-hours-gainers-losers-3-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (3/12/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='green'>+35.8%</font>. <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='green'>+18.3%</font>. <a href='https://seekingalpha.com/symbol/VNET' title='21Vianet Group'>VNET</a> <font color='green'>+4.5%</font>. <a href='https://seekingalpha.com/symbol/TTEC' title='TTEC Holdings, Inc.'>TTEC</a> <font color='green'>+2.4%</font>. <a href='https://seekingalpha.com/symbol/TROX' title='Tronox Inc.'>TROX</a> <font color='green'>+1.5%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/CVGI' title='Commercial Vehicle Group, Inc.'>CVGI</a> <font color='red'>-19.0%</font>. <a href='https://seekingalpha.com/symbol/TLYS' title='Tilly&#39;s, Inc.'>TLYS</a> <font color='red'>-15.5%</font>. <a href='https://seekingalpha.com/symbol/KURA' title='Kura Oncology'>KURA</a> <font color='red'>-11.8%</font>. <a href='https://seekingalpha.com/symbol/MYGN' title='Myriad Genetics, Inc.'>MYGN</a> <font color='red'>-6.6%</font>. <a href='https://seekingalpha.com/symbol/BL' title='BlackLine'>BL</a> <font color='red'>-5.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338533\" data-linked=\"After Hours Gainers / Losers (3/12/2018)\" data-tweet=\"$PTI $PTI $ALT - After Hours Gainers / Losers (3/12/2018) https://seekingalpha.com/news/3338533-after-hours-gainers-losers-3-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3338533-after-hours-gainers-losers-3-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338530\" data-ts=\"1520890421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FENG\" target=\"_blank\">FENG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338530-phoenix-new-media-guides-light-in-in-line-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phoenix New Media guides light in in-line Q4 results</a></h4><ul>   <li>Phoenix New Media (NYSE:<a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a>) is <font color='red'>off 2.1%</font> in light postmarket trading so far after <a href=\"https://seekingalpha.com/news/3338523-phoenix-new-media-epads-line-beats-revenue\" target=\"_blank\">Q4 results</a> were mostly as expected but contained light revenue guidance for the current quarter.</li>    <li>Q4 revenues were up 12.1% Y/Y in renminbi terms, and net ad revenues grew 16.3% (on the strength of a 62.6% Y/Y gain in mobile ad revenues).</li>    <li>Gross profit rose 22.5% to 253.1M yuan; gross margin rose to 55.1% (non-GAAP) from 49.9%.</li>    <li>Net income attributable to the company fell to 11.8M yuan (about $1.8M) from 39.8M yuan a year ago.</li>    <li>Liquidity at quarter's end was 1.44B yuan (about $220.9M).</li>    <li>For Q1 (based on ASC 606) the company's guiding to revenues of 272.3M-287.3M yuan ($43M-$45.4M in dollar terms, light of consensus for $49.2M). Net ad revenues are expected at 237.2M-247.2M yuan, and paid services revenues are forecast at 35.1M-40.1M yuan.</li>    <li><a href=\"http://ir.ifeng.com/\" target=\"_blank\">Conference call</a> to come at 9 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17099704-phoenix-new-media-reports-fourth-quarter-fiscal-year-2017-unaudited-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3338530\" data-linked=\"Phoenix New Media guides light in in-line Q4 results\" data-tweet=\"$FENG - Phoenix New Media guides light in in-line Q4 results https://seekingalpha.com/news/3338530-phoenix-new-media-guides-light-in-in-line-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3338530-phoenix-new-media-guides-light-in-in-line-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338521\" data-ts=\"1520889145\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338521-amarin-presents-post-hoc-data-on-vascepa-aac-shares-up-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin presents post-hoc data on Vascepa at AAC; shares up 4% after hours</a></h4><ul><li>Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;after hours on light volume on the heels of a data <a href=\"https://seekingalpha.com/pr/17099637-vascepa-icosapent-ethyl-showed-reductions-potentially-atherogenic-lipids-inflammatory-markers\" target=\"_blank\">presentation </a>on Vascepa (icosapent ethyl) at the American College of Cardiology Annual Scientific Session &amp; Expo in Orlando, FL.</li><li>In a post hoc analysis of the ANCHOR study, patients with persistent high triglycerides &#40;TG&#41; and elevated high-sensitivity C-Reactive Protein (hsCRP) on statin therapy who received 4 g/day of Vascepa experienced significant reductions in TG and inflammatory biomarkers without an elevation in bad cholesterol. The 18% reduction in hsCRP versus placebo was statistically significant.</li><li>Top-line data from the large-scale REDUCE-IT study should be available in late Q3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338521\" data-linked=\"Amarin presents post-hoc data on Vascepa at AAC; shares up 4% after hours\" data-tweet=\"$AMRN - Amarin presents post-hoc data on Vascepa at AAC; shares up 4% after hours https://seekingalpha.com/news/3338521-amarin-presents-post-hoc-data-on-vascepa-aac-shares-up-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3338521-amarin-presents-post-hoc-data-on-vascepa-aac-shares-up-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338520\" data-ts=\"1520889013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIT\" target=\"_blank\">WIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338520-wipro-closesplus-5_7-after-elliott-adr-purchase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wipro closes +5.7% after Elliott ADR purchase</a></h4><ul><li>        Wipro (NYSE:<a href='https://seekingalpha.com/symbol/WIT' title='Wipro Limited'>WIT</a>) closed today&nbsp;<font color='green'>up 5.7%</font>&nbsp;to $5.77 after Elliott Management <a href=\"https://www.sec.gov/Archives/edgar/data/1048445/000114036118008180/xslForm13F_X01/form13fInfoTable.xml\" target=\"_blank\">disclosed buying</a> 1.86M American Depository Receipts of the company.</li><li>               Wipro have since&nbsp;<font color='red'>slipped 0.8%</font>&nbsp;aftermarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338520\" data-linked=\"Wipro closes +5.7% after Elliott ADR purchase\" data-tweet=\"$WIT - Wipro closes +5.7% after Elliott ADR purchase https://seekingalpha.com/news/3338520-wipro-closesplus-5_7-after-elliott-adr-purchase?source=tweet\" data-url=\"https://seekingalpha.com/news/3338520-wipro-closesplus-5_7-after-elliott-adr-purchase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338493\" data-ts=\"1520886764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADXS\" target=\"_blank\">ADXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338493-fda-halts-advaxis-phase-1-2-study-of-axalimogene-filolisbac-after-patient-death\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA halts Advaxis Phase 1/2 study of axalimogene filolisbac after patient death</a></h4><ul><li>Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis Inc.'>ADXS</a>) <a href=\"https://seekingalpha.com/pr/17099581-advaxis-reports-fiscal-2018-first-quarter-financial-results-announces-clinical-hold\" target=\"_blank\">reports </a>that the FDA has placed its Phase 1/2 clinical trial assessing the combination of axalimogene filolisbac and AstraZeneca's (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) IMFINZI (durvalumab) in patients with advanced, recurrent/refractory human papillomavirus &#40;HPV&#41;-associated cervical cancer and HPV-associated head and neck cancer on clinical hold.</li><li>The agency took action after receiving a report of a patient death due to respiratory failure after the sixth treatment cycle. The company says it, along with its partner, will work closely with the FDA to investigate the event and resolve the clinical hold.</li><li>The company says its other clinical programs will continue as is.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>22%</font>&nbsp;premarket on Tuesday, March 13, on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338493\" data-linked=\"FDA halts Advaxis Phase 1/2 study of axalimogene filolisbac after patient death\" data-tweet=\"$ADXS $ADXS $AZN - FDA halts Advaxis Phase 1/2 study of axalimogene filolisbac after patient death https://seekingalpha.com/news/3338493-fda-halts-advaxis-phase-1-2-study-of-axalimogene-filolisbac-after-patient-death?source=tweet\" data-url=\"https://seekingalpha.com/news/3338493-fda-halts-advaxis-phase-1-2-study-of-axalimogene-filolisbac-after-patient-death\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338491\" data-ts=\"1520886624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338491-coupa-softwareplus-2_2-on-q4-beats-upside-fy-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coupa Software +2.2% on Q4 beats, upside FY guidance</a></h4><ul><li>        Coupa Software (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a>) shares&nbsp;<font color='green'>gain 2.2%</font>&nbsp;aftermarket on a Q4 results that beat estimates with a 42% Y/Y revenue growth. Mixed Q1 guidance has revenue from $51M to $51.5M (consensus: $49.46M) and EPS from -$0.13 to -$0.11 (consensus: -$0.11).&nbsp;</li><li>        Upside FY19 guidance has revenue from $227M to $230M (consensus: $226.82M) and EPS from -$0.28 to -$0.23 (consensus: -$0.29).</li><li>               Earnings call is scheduled for 5 PM ET with a webcast available <a href=\"http://investors.coupa.com/phoenix.zhtml?c=254436&amp;p=irol-irhome\" target=\"_blank\">here</a>.&nbsp;</li><li>                  <a href=\"https://seekingalpha.com/pr/17099578-coupa-software-reports-fourth-quarter-and-full-year-fiscal-2018-financial-results\" target=\"_blank\">Press release</a>&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3338459-coupa-software-beats-0_17-beats-revenue\" target=\"_blank\">Coupa Software beats by $0.17, beats on revenue</a> (March 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3338491\" data-linked=\"Coupa Software +2.2% on Q4 beats, upside FY guidance\" data-tweet=\"$COUP - Coupa Software +2.2% on Q4 beats, upside FY guidance https://seekingalpha.com/news/3338491-coupa-softwareplus-2_2-on-q4-beats-upside-fy-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3338491-coupa-softwareplus-2_2-on-q4-beats-upside-fy-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338483\" data-ts=\"1520886151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MB\" target=\"_blank\">MB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338483-mindbody-acquires-booker-software-for-150m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mindbody acquires Booker Software for $150M</a></h4><ul><li>        Mindbody (NASDAQ:<a href='https://seekingalpha.com/symbol/MB' title='Mindbody'>MB</a>) will <a href=\"https://seekingalpha.com/pr/17099549-mindbody-acquire-booker-software\" target=\"_blank\">acquire Booker Software</a>, which has a cloud-based enterprise management platform for salons and spas. Mindbody will pay $150M in cash and the assumption of unvested options.</li><li>               Booker Software also provides the Frederick automated marketing software for wellness businesses.&nbsp;</li><li>               The acquisition adds about 10K salons and spas to Mindbody&rsquo;s marketplace. Booker earned approximately $25M in subscription and payments revenue last year.&nbsp;</li><li>               Deal is expected to close in Q2.&nbsp;</li><li>               Mindbody shares are&nbsp;<font color='red'>down 0.2%</font>&nbsp;aftermarket to $39.89.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338483\" data-linked=\"Mindbody acquires Booker Software for $150M\" data-tweet=\"$MB - Mindbody acquires Booker Software for $150M https://seekingalpha.com/news/3338483-mindbody-acquires-booker-software-for-150m?source=tweet\" data-url=\"https://seekingalpha.com/news/3338483-mindbody-acquires-booker-software-for-150m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338480\" data-ts=\"1520886035\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFIX\" target=\"_blank\">SFIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338480-active-customers-up-31-stitch-fix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Active customers up 31% at Stitch Fix</a></h4><ul>     <li>Stitch Fitch (NASDAQ:<a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a>) reports active customer count rose 31% Y/Y in <a href=\"https://seekingalpha.com/pr/17099572-stitch-fix-announces-second-quarter-fiscal-2018-financial-results\" target=\"_blank\">Q4</a> to 2.5M.</li>     <li>Revenue increased 24% to $296M during the quarter. Operating income jumped to $15.61M fom $887K a year ago,</li>     <li>\"In addition to strong momentum across our men&rsquo;s and women&rsquo;s categories, we&rsquo;re excited about the potential of Extras, a new capability that allows us to serve more of our client&rsquo;s wardrobe, while increasing incremental revenue,\" says CEO Katrina Lake.</li>     <li>SFIX&nbsp;<font color='red'>-4.64%</font>&nbsp;AH after rallying 6.86% before the report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338480\" data-linked=\"Active customers up 31% at Stitch Fix\" data-tweet=\"$SFIX - Active customers up 31% at Stitch Fix https://seekingalpha.com/news/3338480-active-customers-up-31-stitch-fix?source=tweet\" data-url=\"https://seekingalpha.com/news/3338480-active-customers-up-31-stitch-fix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338470\" data-ts=\"1520885624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PMTS\" target=\"_blank\">PMTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338470-cpi-card-group-beats-0_05-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CPI Card Group beats by $0.05, beats on revenue</a></h4><ul><li>CPI Card Group (NASDAQ:<a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a>): Q4 EPS of -$0.03 <font color='green'>beats by $0.05</font>.</li><li>Revenue of $65M (-3.5% Y/Y) <font color='green'>beats by $3.47M</font>.</li><li>Shares <font color='green'>+1.9%</font>.</li><li><a href='https://seekingalpha.com/pr/17099588-cpi-card-group-inc-reports-fourth-quarter-full-year-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3338470\" data-linked=\"CPI Card Group beats by $0.05, beats on revenue\" data-tweet=\"$PMTS - CPI Card Group beats by $0.05, beats on revenue https://seekingalpha.com/news/3338470-cpi-card-group-beats-0_05-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3338470-cpi-card-group-beats-0_05-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338462\" data-ts=\"1520885392\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BVX\" target=\"_blank\">BVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338462-bovie-medical-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bovie Medical beats by $0.02, beats on revenue</a></h4><ul><li>Bovie Medical (NYSEMKT:<a href='https://seekingalpha.com/symbol/BVX' title='Bovie Medical Corporation'>BVX</a>): Q4 EPS of -$0.03 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $11.35M (+19.6% Y/Y) <font color='green'>beats by $1.5M</font>.</li><li>Shares <font color='green'>+7.7%</font>.</li><li><a href='https://seekingalpha.com/pr/17099552-bovie-medical-corporation-reports-fourth-quarter-full-year-2017-financial-results-provides'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3338462\" data-linked=\"Bovie Medical beats by $0.02, beats on revenue\" data-tweet=\"$BVX - Bovie Medical beats by $0.02, beats on revenue https://seekingalpha.com/news/3338462-bovie-medical-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3338462-bovie-medical-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338459\" data-ts=\"1520885245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338459-coupa-software-beats-0_17-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coupa Software beats by $0.17, beats on revenue</a></h4><ul><li>Coupa Software (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a>): Q4 EPS of $0.02 <font color='green'>beats by $0.17</font>.</li><li>Revenue of $53.8M (+41.5% Y/Y) <font color='green'>beats by $5.14M</font>.</li><li>Shares <font color='green'>+2%</font>.</li><li><a href='https://seekingalpha.com/pr/17099578-coupa-software-reports-fourth-quarter-and-full-year-fiscal-2018-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3338459\" data-linked=\"Coupa Software beats by $0.17, beats on revenue\" data-tweet=\"$COUP - Coupa Software beats by $0.17, beats on revenue https://seekingalpha.com/news/3338459-coupa-software-beats-0_17-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3338459-coupa-software-beats-0_17-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338447\" data-ts=\"1520884665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338447-apple-music-hits-38m-paid-subscribers-apple-orders-first-animated-series\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple Music hits 38M paid subscribers; Apple orders first animated series</a></h4><ul><li>        Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) Music <a href=\"https://in.reuters.com/article/apple-music/apple-music-hits-38-million-paid-subscribers-idINKCN1GO2G8?feedType=RSS&amp;feedName=businessNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FINbusinessNews+%28News+%2F+IN+%2F+Business+News%29\" target=\"_blank\">hits 38M paid subscribers</a>, up 2M from last month, according to the company.</li><li>               Spotify ended last year with 71M premium subscribers.&nbsp;</li><li>               Amazon Music Unlimited has 16M paid subscribers, Pandora has 5.48M total subscribers, and Google doesn&rsquo;t release paid subscriber numbers for Google Play Music.&nbsp;</li><li>               Adding to its growing list of original programming, Apple <a href=\"http://variety.com/2018/tv/news/apple-animated-musical-comedy-central-park-bobs-burgers-1202724158/\" target=\"_blank\">signs its first animated series</a> with a show from Loren Bouchard, creator of &ldquo;Bob&rsquo;s Burgers&rdquo;. The show got a two-season, 26-episode order.&nbsp;</li><li>               The show &ldquo;Central Park&rdquo; is a musical comedy about a family saving the titular park (and the world.) Written by Bouchard, Josh Gad, and Nora Smith, Park will star Gad, Leslie Odom Jr., Kristen Bell, Stanley Tucci, Daveed Diggs, and Kathryn Hahn.&nbsp; &nbsp;</li><li>Apple shares are&nbsp;<font color='green'>up 1.1%</font>&nbsp;near close.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338376-apple-acquires-magazine-subscription-app-texture\" target=\"_blank\">Apple acquires magazine subscription app Texture</a> (March 12)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338411-apple-interested-studios-netflix\" target=\"_blank\">Apple more interested in studios than Netflix</a> (March 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3338447\" data-linked=\"Apple Music hits 38M paid subscribers; Apple orders first animated series\" data-tweet=\"$AAPL - Apple Music hits 38M paid subscribers; Apple orders first animated series https://seekingalpha.com/news/3338447-apple-music-hits-38m-paid-subscribers-apple-orders-first-animated-series?source=tweet\" data-url=\"https://seekingalpha.com/news/3338447-apple-music-hits-38m-paid-subscribers-apple-orders-first-animated-series\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338446\" data-ts=\"1520884639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338446-tesla-rallies-after-musk-sxsw-appearance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla rallies after Musk SXSW appearance</a></h4><ul>     <li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) is&nbsp;<font color='green'>up 5.66%</font>&nbsp;as news of a temporary Model 3 production pause doesn't faze investors.</li>     <li>The upward move in Tesla is being attributed by Bloomberg to positive comments Elon Musk made at SXSW on the timetable for self-driving technology.</li>     <li>Musk <a href=\"http://www.businessinsider.com/elon-musk-ai-more-dangerous-than-nuclear-weapons-sxsw-2018-3\" target=\"_blank\">sees</a> self-driving cars being able to handle all modes of driving by the end of 2019 and sees Tesla's autopilot safer than human drivers within two years.</li>      <li>As for the Model 3 news, there's some optimism that the production break will lead to a faster run-rate when the line is buzzing again.</li>  <li>Today's pop for Tesla is the biggest in more than two months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338446\" data-linked=\"Tesla rallies after Musk SXSW appearance\" data-tweet=\"$TSLA - Tesla rallies after Musk SXSW appearance https://seekingalpha.com/news/3338446-tesla-rallies-after-musk-sxsw-appearance?source=tweet\" data-url=\"https://seekingalpha.com/news/3338446-tesla-rallies-after-musk-sxsw-appearance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>215&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338441\" data-ts=\"1520883885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHERF\" target=\"_blank\">SHERF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338441-sherritt-says-investors-approached-hoping-for-cobalt-deals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sherritt says investors have approached hoping for cobalt deals</a></h4><ul>     <li>Sherritt International (<a href='https://seekingalpha.com/symbol/SHERF' title='Sherritt International Corp.'>OTCPK:SHERF</a> <font color='green'>+6.3%</font>) surges after CEO&nbsp;David Pathe says the company has been <a href=\"https://www.bloomberg.com/news/articles/2018-03-12/investors-hunting-cobalt-deals-approached-sherritt-ceo-says\" target=\"_blank\">approached by investors</a> seeking to buy a share of its cobalt production as a way of gaining exposure to the battery metal.</li>     <li>Sherritt, which has stakes in nickel-cobalt mines in Cuba and Madagascar, would consider selling cobalt in a streaming deal if the terms were attractive enough, Pathe says, adding that he sees no urgency as prices continue to rise.</li>     <li>&ldquo;There are more and more people getting really bullish on cobalt now,&rdquo; the CEO says, predicting the price may surpass its 2008 highs and rise above $55/lb. in the next 12-18 months from the current ~$40/lb.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338441\" data-linked=\"Sherritt says investors have approached hoping for cobalt deals\" data-tweet=\"$SHERF - Sherritt says investors have approached hoping for cobalt deals https://seekingalpha.com/news/3338441-sherritt-says-investors-approached-hoping-for-cobalt-deals?source=tweet\" data-url=\"https://seekingalpha.com/news/3338441-sherritt-says-investors-approached-hoping-for-cobalt-deals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338439\" data-ts=\"1520883120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPL\" target=\"_blank\">UPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338439-ultra-petroleum-announces-strong-initial-test-rate-on-new-well\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ultra Petroleum announces strong initial test rate on new well</a></h4><ul>     <li>Ultra Petroleum (<a href='https://seekingalpha.com/symbol/UPL' title='Ultra Petroleum Corp.'>UPL</a> <font color='green'>+10.9%</font>) surges ~10% after reporting its Warbonnet 9-23 A-2H well <a href=\"https://seekingalpha.com/pr/17098679-ultra-petroleum-announces-54_5-mmcfe-d-initial-test-rate-recent-lower-lance-horizontal-well\" target=\"_blank\">achieved</a> a 24-hour initial production rate of 54.5M cfe/day on March 3.</li>     <li>UPL expects at least two additional horizontal wells will be online in April, with results available for its next quarterly earnings release in early May.</li>     <li>The company estimates FY 2018 adjusted EBITDA of $539M, based on a production guidance midpoint of 285B cfe and a price realization if $2.84/Mcfe, higher than its estimate of $2.82/Mcfe shown in its Feb. 28 investor presentation.</li>     <li>UPL also says it named Evan Lederman, partner at top shareholder Fir Tree Partners, as its new Chairman, and selects two other board members.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338439\" data-linked=\"Ultra Petroleum announces strong initial test rate on new well\" data-tweet=\"$UPL $UPLC - Ultra Petroleum announces strong initial test rate on new well https://seekingalpha.com/news/3338439-ultra-petroleum-announces-strong-initial-test-rate-on-new-well?source=tweet\" data-url=\"https://seekingalpha.com/news/3338439-ultra-petroleum-announces-strong-initial-test-rate-on-new-well\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338438\" data-ts=\"1520882614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338438-kroger-and-instacart-add-to-delivery-coverage-area\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kroger and Instacart add to delivery coverage area</a></h4><ul>     <li>Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='green'>+0.2%</font>) and Instacart (<a href='https://seekingalpha.com/symbol/ICART' title='Instacart'>ICART</a>) are expanding their partnership by increasing the customer delivery coverage area this year.</li>     <li>Kroger now offers home delivery in 45 markets for its various chains through Instacart and other delivery partners.</li><li>More deals between Instacart and grocery companies are expected as the same-day grocery upstart looks to move <a href=\"https://seekingalpha.com/news/3338357-competition-fears-around-blue-apron\" target=\"_blank\">beyond Amazon</a>.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/17099468-kroger-instacart-expand-partnership\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3338438\" data-linked=\"Kroger and Instacart add to delivery coverage area\" data-tweet=\"$KR $KR $ICART - Kroger and Instacart add to delivery coverage area https://seekingalpha.com/news/3338438-kroger-and-instacart-add-to-delivery-coverage-area?source=tweet\" data-url=\"https://seekingalpha.com/news/3338438-kroger-and-instacart-add-to-delivery-coverage-area\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338437\" data-ts=\"1520882428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFTBF\" target=\"_blank\">SFTBF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338437-nyt-softbank-wants-vision-fund-fortress-in-new-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NYT: SoftBank wants Vision Fund, Fortress in new business</a></h4><ul><li>        <a href=\"https://www.nytimes.com/2018/03/11/business/softbank-private-equity.html?utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=newsletter_axiosprorata&amp;stream=top-stories\" target=\"_blank\">NYT reports</a> SoftBank (<a href='https://seekingalpha.com/symbol/SFTBF' title='SoftBank Group'>OTCPK:SFTBF</a>, <a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a>) wants to create a new asset management business to house its Vision Fund and Fortress Investment Group.</li><li>               The tech-focused Vision Fund and Fortress, which manages $40B, would still operate as separate entities.&nbsp;</li><li>                  The new SoftBank Financial Services would give the company access to alternative investments (private equity, hedge funds, distressed debt) that come with high fees and decade-long cash lockdowns.    &nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338315-charter-plus-1_5-percent-new-reports-softbank-buildup\" target=\"_blank\">Charter +1.5% on new reports of SoftBank buildup</a> (March 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3338437\" data-linked=\"NYT: SoftBank wants Vision Fund, Fortress in new business\" data-tweet=\"$SFTBF $SFTBF $SFTBY - NYT: SoftBank wants Vision Fund, Fortress in new business https://seekingalpha.com/news/3338437-nyt-softbank-wants-vision-fund-fortress-in-new-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3338437-nyt-softbank-wants-vision-fund-fortress-in-new-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338436\" data-ts=\"1520882169\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338436-blue-apronminus-10-sentiment-stays-negative\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron -10% as sentiment stays negative</a></h4><ul> <li>Blue Apron (NYSE:<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>) is very close to its all-time low after&nbsp;<font color='red'>falling 10.5%</font>&nbsp;on the day.</li> <li>Bloomberg reports that a block trade of 700K shares crossed this afternoon at $2.12.</li> <li>Earlier: <a href=\"https://seekingalpha.com/news/3338357-competition-fears-around-blue-apron\" target=\"_blank\">Competition fears around Blue Apron</a> (March 12)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338436\" data-linked=\"Blue Apron -10% as sentiment stays negative\" data-tweet=\"$APRN - Blue Apron -10% as sentiment stays negative https://seekingalpha.com/news/3338436-blue-apronminus-10-sentiment-stays-negative?source=tweet\" data-url=\"https://seekingalpha.com/news/3338436-blue-apronminus-10-sentiment-stays-negative\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338433\" data-ts=\"1520881617\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTTR\" target=\"_blank\">RTTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338433-ritter-pharmas-lead-candidate-shows-encouraging-action-in-mid-stage-lactose-intolerance-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ritter Pharma&#39;s lead candidate shows encouraging action in mid-stage lactose intolerance study; shares ahead 6%</a></h4><ul><li>Nano cap Ritter Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a> <font color='green'>+6.2%</font>) is up on more than a 4x surge in volume on the heels of its <a href=\"https://seekingalpha.com/pr/17098512-ritter-pharmaceuticals-reports-microbiome-data-phase-2b-study-rp-g28-promotes-beneficial\" target=\"_blank\">announcement </a>of positive data from a Phase 2b clinical trial assessing lead drug RP-G28 in 377 patients intolerant of lactose.</li><li>After 30 days' treatment with RP-G28, patients experienced a significant increase in lactic acid bacteria in the gut, implying that they would be better able to digest lactose.</li><li>A Phase 3 study should launch next quarter.</li><li><a href=\"http://www.ritterpharmaceuticals.com/product-platform/rpg28\" target=\"_blank\">RP-G28</a>,&nbsp;a highly purified&nbsp;<a href=\"http://en.wikipedia.org/wiki/Galactooligosaccharide\" target=\"_blank\">galactooligosaccharide</a>,&nbsp;is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. If approved, it will be the first drug cleared by the FDA for the indication.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290433-ritter-solidifies-phase-3-program-rp-g28-shares-6-percent\" target=\"_blank\">Ritter solidifies Phase 3 program for RP-G28; shares up 6%</a> (Aug. 18, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3338433\" data-linked=\"Ritter Pharma&#39;s lead candidate shows encouraging action in mid-stage lactose intolerance study; shares ahead 6%\" data-tweet=\"$RTTR - Ritter Pharma&#39;s lead candidate shows encouraging action in mid-stage lactose intolerance study; shares ahead 6% https://seekingalpha.com/news/3338433-ritter-pharmas-lead-candidate-shows-encouraging-action-in-mid-stage-lactose-intolerance-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3338433-ritter-pharmas-lead-candidate-shows-encouraging-action-in-mid-stage-lactose-intolerance-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338432\" data-ts=\"1520881357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCEHY\" target=\"_blank\">TCEHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338432-barclays-ups-tencent-target-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays ups Tencent target ahead of earnings</a></h4><ul><li>        Barclays raises its Tencent (<a href='https://seekingalpha.com/symbol/TCEHY' title='Tencent Holding Ltd. ADR'>OTCPK:TCEHY</a>) price target from $59 to $64 ahead of next Wednesday&rsquo;s earnings report.</li><li>               Firm cites the organic development of gaming and payment as key drivers with content costs and payment investments as margin drags.&nbsp;</li><li>               Barclays notes that the Q4 margin decline for Alibaba&rsquo;s Ant Financial displays intensifying competition in the online payment industry.&nbsp;</li><li>               Source: Briefing.com.&nbsp;</li><li>               Tencent shares are&nbsp;<font color='green'>up 0.4%</font>&nbsp;to $58.38&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338432\" data-linked=\"Barclays ups Tencent target ahead of earnings\" data-tweet=\"$TCEHY - Barclays ups Tencent target ahead of earnings https://seekingalpha.com/news/3338432-barclays-ups-tencent-target-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3338432-barclays-ups-tencent-target-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338431\" data-ts=\"1520881302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NETE\" target=\"_blank\">NETE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338431-technology-top-gainers-losers-of-3_00-pm-3-12-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3.00 pm (3/12/18)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='green'>+17%</font>. IFON <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TNTR-OLD' title='Tintri, Inc.'>TNTR-OLD</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/HCHC' title='HC2 Holdings, Inc.'>HCHC</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RBBN' title='Ribbon Communications Inc.'>RBBN</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/INTT' title='inTest Corporation'>INTT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SPOK' title='Spok Holdings, Inc.'>SPOK</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338431\" data-linked=\"Technology - Top Gainers / Losers as of 3.00 pm (3/12/18)\" data-tweet=\"$NETE $NETE $OCLR - Technology - Top Gainers / Losers as of 3.00 pm (3/12/18) https://seekingalpha.com/news/3338431-technology-top-gainers-losers-of-3_00-pm-3-12-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3338431-technology-top-gainers-losers-of-3_00-pm-3-12-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338426\" data-ts=\"1520880273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338426-twilioplus-3_3-on-flex-launch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twilio +3.3% on Flex launch</a></h4><ul><li>        Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>) <a href=\"https://techcrunch.com/2018/03/12/twilio-launches-flex-a-fully-programmable-contact-center/?ncid=rss&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\">launches Flex</a>, a customizable contact center solution.</li><li>               Flex combines the existing Twilio setup, which has nearly 40B interactions a year, with an interface that allows enterprises to create a full stack contact center with a full GUI.&nbsp;</li><li>               Twilio shares are&nbsp;<font color='green'>up 3.3%</font>&nbsp;to $40.80.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338426\" data-linked=\"Twilio +3.3% on Flex launch\" data-tweet=\"$TWLO - Twilio +3.3% on Flex launch https://seekingalpha.com/news/3338426-twilioplus-3_3-on-flex-launch?source=tweet\" data-url=\"https://seekingalpha.com/news/3338426-twilioplus-3_3-on-flex-launch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338425\" data-ts=\"1520880149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROSE\" target=\"_blank\">ROSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338425-rosehill-resources-says-marchs-first-week-production-average-rose-to-record\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosehill Resources says March&#39;s first week production average rose to record</a></h4><ul>     <li>Rosehill Resources (<a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a> <font color='green'>+3.8%</font>) is rising after reporting new well performance in the Permian Basin <a href=\"https://seekingalpha.com/pr/17098592-rosehill-resources-provides-operational-update\" target=\"_blank\">increased average production</a> for first week of March to a record high of 13K net boe/day (72% oil) with a significant increase expected by the end of the month.</li>     <li>The company says net daily production topped 10K net boe/day in late December but fell below 9K boe/day in January due to severe cold weather, simultaneous operations downtime and offset operator activities before improving in February to nearly 11K boe/day.</li>     <li>ROSE also says development in White Wolf is underway with surveying, staking and permitting activities, with plans to begin drilling four wells in early Q2; it expects to drill 16-22 new wells in the White Wolf area this year and complete 12-16.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338425\" data-linked=\"Rosehill Resources says March&#39;s first week production average rose to record\" data-tweet=\"$ROSE - Rosehill Resources says March&#39;s first week production average rose to record https://seekingalpha.com/news/3338425-rosehill-resources-says-marchs-first-week-production-average-rose-to-record?source=tweet\" data-url=\"https://seekingalpha.com/news/3338425-rosehill-resources-says-marchs-first-week-production-average-rose-to-record\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338424\" data-ts=\"1520879502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MACK\" target=\"_blank\">MACK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338424-merrimack-pharma-down-10-on-expanded-enrollment-in-mid-stage-study-of-mmminus-121\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merrimack Pharma down 10% on expanded enrollment in mid-stage study of MM-121</a></h4><ul><li>Thinly traded micro cap Merrimack Pharmaceuticals (<a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='red'>-9.8%</font>) slips on almost double normal volume, albeit on turnover of only 224K shares, in reaction to its planned <a href=\"https://seekingalpha.com/pr/17098547-merrimack-strengthens-sherloc-study-mmminus-121-non-small-cell-lung-cancer\" target=\"_blank\">enrollment increase</a> in the Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02387216?intr=mm-121&amp;spons=merrimack&amp;phase=1&amp;rank=4\" target=\"_blank\">SHERLOC </a>study evaluating MM-121 (seribantumab) in patients with heregulin-positive non-small lung cancer who have progressed after platinum-based chemo.</li><li>The company plans to increase the number of participants to 100 from 80 citing rapid enrollment and \"robust clinical interest.\" Frequently, however, a sponsor increases enrollment to improve the chances of a statistically valid result. Top-line data should be available in H2. The primary endpoint is progression-free survival for MM-121 + docetaxel compared to docetaxel alone.</li><li>Seribantumab is a fully human monoclonal antibody that binds to a receptor on tumor cells called&nbsp;<a href=\"https://en.wikipedia.org/wiki/ERBB3\" target=\"_blank\">ErbB3</a>, which is activated by&nbsp;<a href=\"http://mcr.aacrjournals.org/content/1/3/165.full\" target=\"_blank\">heregulin</a>. ErbB3 signaling is thought to play a key role in tumor growth and resistance to cytotoxic and anti-endocrine therapies. Seribantumab blocks ErbB3 signaling which enhances the anti-tumor effect of the combination therapy.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3334233-mid-stage-study-underway-merrimacks-seribantumab-breast-cancer-shares-1-percent\" target=\"_blank\">Mid-stage study underway on Merrimack's seribantumab in breast cancer; shares up 1%</a> (Feb. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3338424\" data-linked=\"Merrimack Pharma down 10% on expanded enrollment in mid-stage study of MM-121\" data-tweet=\"$MACK - Merrimack Pharma down 10% on expanded enrollment in mid-stage study of MM-121 https://seekingalpha.com/news/3338424-merrimack-pharma-down-10-on-expanded-enrollment-in-mid-stage-study-of-mmminus-121?source=tweet\" data-url=\"https://seekingalpha.com/news/3338424-merrimack-pharma-down-10-on-expanded-enrollment-in-mid-stage-study-of-mmminus-121\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338419\" data-ts=\"1520878045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LNTH\" target=\"_blank\">LNTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338419-lantheus-imaging-agent-lmi-1195-shows-positive-effect-in-mid-stage-study-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lantheus imaging agent LMI 1195 shows positive effect in mid-stage study; shares ahead 5%</a></h4><ul><li>Thinly traded Lantheus Holdings (<a href='https://seekingalpha.com/symbol/LNTH' title='Lantheus Holdings'>LNTH</a> <font color='green'>+4.7%</font>) is up, albeit on lower-than-normal volume, on the heels of its <a href=\"https://seekingalpha.com/pr/17099073-lantheus-presents-new-data-novel-cardiac-pet-imaging-agent-lmi-1195-development-diagnostic\" target=\"_blank\">announcement </a>of new positive data from a Phase 2 clinical evaluating imaging agent LMI 1195 for use in cardiac positron tomography &#40;PET&#41; to assess myocardial presynaptic sympathetic nerve function. The data are being presented at the American College of Cardiology Annual Scientific Session &amp; Expo in Orlando, FL.</li><li>The results showed that LMI 1195 delivered a comparable measure of cardiac sympathetic nerve function and more favorable kinetics for early cardiac imaging as carbon-11 hydroxyephedrine, the imaging agent typically used to assess the risk of patients with ischemic cardiomyopathy &#40;ICM&#41; who are being considered for implantable cardiac defibrillators. The value-add for LMI 1195 is its longer half-life which would not require an on-site cyclotron.</li><li>Altered sympathetic nervous system function is associated with heart failure and sudden death.</li><li>A Phase 3 study in ICM patients should launch later this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338419\" data-linked=\"Lantheus imaging agent LMI 1195 shows positive effect in mid-stage study; shares ahead 5%\" data-tweet=\"$LNTH - Lantheus imaging agent LMI 1195 shows positive effect in mid-stage study; shares ahead 5% https://seekingalpha.com/news/3338419-lantheus-imaging-agent-lmi-1195-shows-positive-effect-in-mid-stage-study-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3338419-lantheus-imaging-agent-lmi-1195-shows-positive-effect-in-mid-stage-study-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338420\" data-ts=\"1520878042\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRDM\" target=\"_blank\">IRDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338420-iridium-preps-for-fifth-next-launch-spacex\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iridium preps for fifth NEXT launch with SpaceX</a></h4><ul>   <li>Iridium Communications (<a href=\"http://seekingalpha.com/symbol/IRDM\" target=\"_blank\">IRDM</a> <font color='red'>-5%</font>) is progressing on a fifth launch of its next-gen satellite constellation, with word that all 10 of its NEXT satellites are at Vandenberg Air Force Base.</li>    <li>The satellites are in processing at SpaceX's West Coast site; the launch, scheduled for March 29, will be the second to use a \"flight-proven\" SpaceX Falcon 9 rocket.</li>    <li>The launch will bring Iridium's in-space NEXT count to 50. The latest 10 will head for Iridium orbital plane 1 and immediately go into service.</li>    <li>Iridium's deal with SpaceX covers delivery of 75 NEXT satellites over eight launches.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338420\" data-linked=\"Iridium preps for fifth NEXT launch with SpaceX\" data-tweet=\"$IRDM - Iridium preps for fifth NEXT launch with SpaceX https://seekingalpha.com/news/3338420-iridium-preps-for-fifth-next-launch-spacex?source=tweet\" data-url=\"https://seekingalpha.com/news/3338420-iridium-preps-for-fifth-next-launch-spacex\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338418\" data-ts=\"1520877826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RKDA\" target=\"_blank\">RKDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338418-energy-materials-top-gainers-losers-of-2-00-pm-3-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm (3/12/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='green'>+52%</font>. <a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/PFIE' title='Profire Energy, Inc.'>PFIE</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SRLP' title='Sprague Resources LP'>SRLP</a> <font color='green'>+8%</font>. SGY <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/METC' title='Ramaco'>METC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TAT' title='TransAtlantic Petroleum Ltd.'>TAT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SOI' title='Solaris Oilfield Infrastructure'>SOI</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338418\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm (3/12/2018)\" data-tweet=\"$RKDA $RKDA $PEIX - Energy/Materials - Top Gainers / Losers as of 2:00 pm (3/12/2018) https://seekingalpha.com/news/3338418-energy-materials-top-gainers-losers-of-2-00-pm-3-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3338418-energy-materials-top-gainers-losers-of-2-00-pm-3-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338409\" data-ts=\"1520876422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMCC\" target=\"_blank\">FMCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338409-rbc-says-mortgage-insurers-are-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC says mortgage insurers are a buy</a></h4><ul><li>RBC analyst Mark Dwelle responds to earlier reports of a partnership between Freddie Mac (<a href='https://seekingalpha.com/symbol/FMCC' title='Freddie Mac'>OTCQB:FMCC</a>) and Arch Capital (NASDAQ:<a href='https://seekingalpha.com/symbol/ACGL' title='Arch Capital Group Ltd.'>ACGL</a>) saying, investors should buy the weakness in private mortgage insurers as the impact will not be as bad as the stock selloff.</li><li>The pilot program being tested by Freddie Mac and Arch Capital has investors concerned, but Dwelle notes that the plan is a test program and it only impacts the \"singles\" business. The plan will need be adopted by Fannie Mae (<a href='https://seekingalpha.com/symbol/FNMA' title='Fannie Mae'>OTCQB:FNMA</a>) and other lenders to be of significant immediate concern.</li><li>Radian Group (<a href='https://seekingalpha.com/symbol/RDN' title='Radian Group, Inc.'>RDN</a> <font color='red'>-10.6%</font>),&nbsp;MGIC (<a href='https://seekingalpha.com/symbol/MTG' title='MGIC Investment Corporation'>MTG</a> <font color='red'>-9.8%</font>), NMI Holdings (<a href='https://seekingalpha.com/symbol/NMIH' title='NMI Holdings, Inc.'>NMIH</a> <font color='red'>-10.1%</font>), and Essent Group (<a href='https://seekingalpha.com/symbol/ESNT' title='Essent Group Ltd.'>ESNT</a> <font color='red'>-10.4%</font>)&nbsp;all crashed on the news earlier today.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338381-mortgage-insurers-crash-freddie-mac-partnership-arch-capital\" target=\"_blank\">Mortgage insurers crash on Freddie Mac partnership with Arch Capital</a> (March 12)</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3338409\" data-linked=\"RBC says mortgage insurers are a buy\" data-tweet=\"$FMCC $FMCC $ACGL - RBC says mortgage insurers are a buy https://seekingalpha.com/news/3338409-rbc-says-mortgage-insurers-are-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3338409-rbc-says-mortgage-insurers-are-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338411\" data-ts=\"1520875970\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338411-apple-interested-in-studios-netflix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple more interested in studios than Netflix</a></h4><ul>     <li>Netflix (<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='red'>-3.5%</font>) tracks a little lower after Apple services chief Eddy Cue said at SWSX that the company would rather buy a studio than the streaming juggernaut.</li>     <li>\"We don&rsquo;t know anything about making television,\"  Cue stated.</li><li>Apple-Netflix speculation has drifted about for years.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338344-outsized-netflix-rally-questioned-ft\" target=\"_blank\">Outsized Netflix rally questioned by FT</a> (March 12)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338411\" data-linked=\"Apple more interested in studios than Netflix\" data-tweet=\"$NFLX - Apple more interested in studios than Netflix https://seekingalpha.com/news/3338411-apple-interested-in-studios-netflix?source=tweet\" data-url=\"https://seekingalpha.com/news/3338411-apple-interested-in-studios-netflix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>88&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338410\" data-ts=\"1520875961\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHVN\" target=\"_blank\">BHVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338410-biohaven-pharma-restructures-license-agreement-bristol-myers-shares-down-3-on-discounted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biohaven Pharma restructures license agreement with Bristol-Myers; shares down 3% on discounted stock deal</a></h4><ul><li>Biohaven Pharmaceutical Holding Company (<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a> <font color='red'>-2.7%</font>) has revamped its <a href=\"https://seekingalpha.com/pr/17098467-biohaven-restructures-license-agreement-bristol-myers-squibb-reduce-royalties-payable\" target=\"_blank\">license agreement</a> with Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-1%</font>) related to migraine candidates rimegepant and BHV-3500.</li><li>Under the terms of the new arrangement, the company paid BMY $50M in consideration of a low-single-digit&nbsp;reduction in payable royalties for rimegepant and a mid-single-digit reduction for BHV-3500. The deal also removes BMY's first negotiation rights to regain the intellectual property or enter a license agreement with Biohaven after receiving Phase 3 data on rimegepant and enables Biohaven to out-license either candidate to a third party with a CGRP antibody program.</li><li>Biohaven funded the restructuring via a $55M private placement of 2M common shares at $27.50 per share with institutional investors. The transaction should close on March 14. BHVN shares are currently exchanging hands at ~$29.70.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338410\" data-linked=\"Biohaven Pharma restructures license agreement with Bristol-Myers; shares down 3% on discounted stock deal\" data-tweet=\"$BHVN $BHVN $BMY - Biohaven Pharma restructures license agreement with Bristol-Myers; shares down 3% on discounted stock deal https://seekingalpha.com/news/3338410-biohaven-pharma-restructures-license-agreement-bristol-myers-shares-down-3-on-discounted?source=tweet\" data-url=\"https://seekingalpha.com/news/3338410-biohaven-pharma-restructures-license-agreement-bristol-myers-shares-down-3-on-discounted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338412\" data-ts=\"1520875876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTHP\" target=\"_blank\">GTHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338412-guided-therapeutics-gets-regulatory-approval-for-sale-in-india\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guided Therapeutics gets regulatory approval for sale in India</a></h4><ul>     <li>Guided Therapeutics (<a href='https://seekingalpha.com/symbol/GTHP' title='Guided Therapeutics, Inc.'>OTCPK:GTHP</a> <font color='green'>+52.4%</font>) has received <a href=\"https://seekingalpha.com/pr/17099275-guided-therapeutics-achieves-regulatory-approval-sale-india\" target=\"_blank\">regulatory approval</a> from the Indian Ministry of Health &amp; Family Welfare to allow commercialization of the LuViva device and disposables. The Ministry concluded that the LuViva device is &ldquo;Non Invasive&rdquo;</li>     <li>The company also has plans for commercialization in India.</li>     <li>&ldquo;There are approximately 330 million women who are age appropriate for cervical cancer screening in India,&rdquo; said Gene Cartwright, CEO. &ldquo;Only a small percentage of age appropriate women are screened today in India due to the logistical complications of using other methods of cervical cancer screening. LuViva is an attractive alternative because it doesn&rsquo;t require a patient sample or a laboratory, and a result is given in approximately 1 minute at the point of care.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338412\" data-linked=\"Guided Therapeutics gets regulatory approval for sale in India\" data-tweet=\"$GTHP $GTHP-OLD1 - Guided Therapeutics gets regulatory approval for sale in India https://seekingalpha.com/news/3338412-guided-therapeutics-gets-regulatory-approval-for-sale-in-india?source=tweet\" data-url=\"https://seekingalpha.com/news/3338412-guided-therapeutics-gets-regulatory-approval-for-sale-in-india\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338408\" data-ts=\"1520875428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTY\" target=\"_blank\">PTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338408-party-city-higher-analysts-show-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Party City higher as analysts show confidence</a></h4><ul><li>Party City (<a href='https://seekingalpha.com/symbol/PTY' title='PIMCO Corporate&Income Opportunity Fund'>PTY</a> <font color='green'>+0.2%</font>) shoots higher after analysts back the retailer for improved results.</li><li>Stephens backs its Overweight rating on the retailer, saying margins should continue to improve. BMO Capital hikes its price target to $20 on its belief that there is better visibility on PRTY's sales growth and earnings.</li><li>Shares of Party City are up 25% over the last 90 days.</li><li>Sources: Marketwatch, Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3338408\" data-linked=\"Party City higher as analysts show confidence\" data-tweet=\"$PTY - Party City higher as analysts show confidence https://seekingalpha.com/news/3338408-party-city-higher-analysts-show-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3338408-party-city-higher-analysts-show-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338407\" data-ts=\"1520874829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGRX\" target=\"_blank\">RGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338407-regenerx-nabs-european-patent-covering-rgnminus-352-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RegeneRx nabs European patent covering RGN-352; shares up 2%</a></h4><ul><li>RegeneRx (<a href='https://seekingalpha.com/symbol/RGRX' title='RegeneRx Biopharmaceuticals, Inc.'>OTCQB:RGRX</a> <font color='green'>+2.3%</font>) <a href=\"https://seekingalpha.com/pr/17098856-regenerx-receives-decision-grant-european-patent-treatment-peripheral-neuropathy\" target=\"_blank\">announces </a>that it has received a \"Decision to Grant\" notice from the European Patent Office for a new patent covering the treatment of patients with peripheral neuropathy using Thymosin beta 4, the active ingredient in candidate RGN-352.</li><li><a href=\"http://www.regenerx.com/RGN-352\" target=\"_blank\">RGN-352</a> is in development to treat cardiac damage after a heart attack and chronic heart failure in addition to a range of nervous system disorders.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338407\" data-linked=\"RegeneRx nabs European patent covering RGN-352; shares up 2%\" data-tweet=\"$RGRX - RegeneRx nabs European patent covering RGN-352; shares up 2% https://seekingalpha.com/news/3338407-regenerx-nabs-european-patent-covering-rgnminus-352-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3338407-regenerx-nabs-european-patent-covering-rgnminus-352-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338402\" data-ts=\"1520874045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UCBA\" target=\"_blank\">UCBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338402-financials-top-5-gainers-losers-of-1-00-pm-03-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (03/12/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/UCBA' title='United Community Bancorp'>UCBA</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/LOOP' title='Loop Industries, Inc.'>LOOP</a> <font color='green'>+23%</font>.<a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NMIH' title='NMI Holdings, Inc.'>NMIH</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/RDN' title='Radian Group, Inc.'>RDN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/MTG' title='MGIC Investment Corporation'>MTG</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ESNT' title='Essent Group Ltd.'>ESNT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CIVB' title='Civista Bancshares, Inc.'>CIVB</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338402\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (03/12/2018)\" data-tweet=\"$UCBA $UCBA $LOOP - Financials - Top 5 Gainers / Losers as of 1:00 PM (03/12/2018) https://seekingalpha.com/news/3338402-financials-top-5-gainers-losers-of-1-00-pm-03-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3338402-financials-top-5-gainers-losers-of-1-00-pm-03-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338397\" data-ts=\"1520874025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338397-portola-pharma-announces-new-interim-data-from-late-stage-study-of-andexxa-shares-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola Pharma announces new interim data from late-stage study of AndexXa; shares down 9%</a></h4><ul><li>Portola Pharmaceuticals (<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a> <font color='red'>-9.3%</font>) is down on almost double normal volume in response to the release of <a href=\"https://seekingalpha.com/pr/17099321-portola-pharmaceuticals-announces-new-interim-results-ongoing-annexaminus-4-study-factor-xa\" target=\"_blank\">new interim data</a> from the Phase 3b/4 study, ANNEXA-4, evaluating AndexXa (andexanet alfa) in patients experiencing acute major bleeding while on Factor Xa inhibitor therapy. The data were presented at the American College of Cardiology Annual Scientific Session &amp; Expo in Orlando, FL.</li><li>Results from 132 subjects qualified for efficacy showed an 83% rate of good/excellent hemostasis (bleeding stopped) over a 12-hour period post-infusion. Blood clotting events occurred in 11% of patients and 12% died. The company says the data are consistent with previously released results.</li><li>Investors appear to have been hoping for better data that would lessen the risk that the FDA will require another clinical trial. Its current action date for the company's resubmitted marketing application is May 4.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3206028-portolas-andexxa-effective-reversing-factor-xa-associated-bleeding-late-stage-study-shares\" target=\"_blank\">Portola's AndexXa effective in reversing Factor Xa-associated bleeding in late-stage study; shares ahead 6% premarket</a> (Aug. 30, 2016)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3335582-portola-pharma-17-percent-premarket-potential-delay-u-s-approval-andexxa\" target=\"_blank\">Portola Pharma down 17% premarket on potential delay in U.S. approval of AndexXa</a> (March 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3338397\" data-linked=\"Portola Pharma announces new interim data from late-stage study of AndexXa; shares down 9%\" data-tweet=\"$PTLA - Portola Pharma announces new interim data from late-stage study of AndexXa; shares down 9% https://seekingalpha.com/news/3338397-portola-pharma-announces-new-interim-data-from-late-stage-study-of-andexxa-shares-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3338397-portola-pharma-announces-new-interim-data-from-late-stage-study-of-andexxa-shares-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338399\" data-ts=\"1520873484\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338399-mellanox-starboard-clash-over-annual-meeting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mellanox, Starboard clash over annual meeting</a></h4><ul><li>        Mellanox (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) <a href=\"https://seekingalpha.com/pr/17098619-mellanox-sends-letter-shareholders\" target=\"_blank\">sends shareholders a letter</a> asking for votes in favor of a plurality voting standard in the event of a contested election and the use of universal proxy cards.</li><li>               The company wants to hold an extraordinary general meeting &#40;EGM&#41; to deal with these issues.&nbsp;</li><li>               Mellanox&rsquo;s board currently has a majority voting structure, which means that the board could have some vacancies if all 11 candidates don&rsquo;t get enough votes. The majority-elected directors would then fill the vacancies.&nbsp; Plurality voting would have all of the board members elected by the shareholders.&nbsp;</li><li>               Universal proxy cards would let shareholders elect any combination of director nominees rather than only submitting one proxy, which is the current setup.&nbsp;</li><li>               The requests follow activist investor Starboard Value nominating a full slate of directors to the Mellanox board. &nbsp;&nbsp;</li><li>               Key quote from Starboard&rsquo;s <a href=\"https://www.prnewswire.com/news-releases/starboard-responds-to-mellanoxs-proposed-extraordinary-general-meeting-egm-in-open-letter-to-mellanox-shareholders-300612362.html\" target=\"_blank\">response</a>: &ldquo;Although neither of these proposals is specifically problematic, there is absolutely no need to delay the 2018 Annual Meeting by three months to accomplish the Company's goal of implementing these changes.&nbsp;Under separate cover, Starboard will be delivering to Mellanox and its advisors today&nbsp;a proposal<b> </b>that would allow both of these governance reforms to be implemented with our support and without the unnecessary three-month delay.&rdquo;&nbsp;&nbsp;</li><li>               Mellanox shares are&nbsp;<font color='green'>up 0.8%</font>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338399\" data-linked=\"Mellanox, Starboard clash over annual meeting\" data-tweet=\"$MLNX - Mellanox, Starboard clash over annual meeting https://seekingalpha.com/news/3338399-mellanox-starboard-clash-over-annual-meeting?source=tweet\" data-url=\"https://seekingalpha.com/news/3338399-mellanox-starboard-clash-over-annual-meeting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338395\" data-ts=\"1520873110\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BXC\" target=\"_blank\">BXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338395-midday-gainers-losers-3-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (3/12/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BXC' title='BlueLinx Holdings, Inc.'>BXC</a> <font color='green'>+83%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='green'>+51%</font>. <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/UCBA' title='United Community Bancorp'>UCBA</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/IMMP' title='Immutep Limited ADR'>IMMP</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/JNP' title='Juniper Pharmaceuticals, Inc.'>JNP</a> <font color='green'>+17%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a> <font color='red'>-81%</font>. <a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='red'>-74%</font>. <a href='https://seekingalpha.com/symbol/SINO' title='Sino-Global Shipping America, Ltd.'>SINO</a> <font color='red'>-34%</font>. <a href='https://seekingalpha.com/symbol/BRID' title='Bridgford Foods Corporation'>BRID</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/PICO' title='PICO Holdings Inc.'>PICO</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/PIXY' title='ShiftPixy'>PIXY</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NMIH' title='NMI Holdings, Inc.'>NMIH</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338395\" data-linked=\"Midday Gainers / Losers (3/12/2018)\" data-tweet=\"$BXC $BXC $RKDA - Midday Gainers / Losers (3/12/2018) https://seekingalpha.com/news/3338395-midday-gainers-losers-3-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3338395-midday-gainers-losers-3-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338391\" data-ts=\"1520872536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTI\" target=\"_blank\">WTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338391-w-and-t-offshore-to-buy-cobalt-energy-s-heidelberg-field-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">W&amp;T Offshore to buy Cobalt Energy\u2019s Heidelberg field interest</a></h4><ul>     <li>W&amp;T Offshore (<a href='https://seekingalpha.com/symbol/WTI' title='W&T Offshore, Inc.'>WTI</a> <font color='green'>+1.6%</font>) says it was the  <a href=\"https://seekingalpha.com/pr/17098549-w-and-t-offshore-successful-bidder-acquire-interest-heidelberg-field-gulf-mexico\" target=\"_blank\">successful bidder</a> on an interest in three blocks in Heidelberg field in the Gulf of Mexico offered in connection with Cobalt Energy's (<a href='https://seekingalpha.com/symbol/CIE' title='Cobalt International Energy, Inc.'>CIE</a>) Chapter 11 bankruptcy  proceedings.</li>     <li>WTI says its $31.1M offer will bring in all of CIE&rsquo;s interest in the Heidelberg field, which includes 9.375% working interest in each of Green Canyon  Blocks 859, 903, and 904; Anadarko&nbsp;Petroleum (<a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='green'>+1.1%</font>) is operator of the field.</li>     <li>February's total gross production from the field was 36.3K boe/day, with CIE's net production from its interest totaling nearly 3K boe/day from five wells.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338391\" data-linked=\"W&amp;T Offshore to buy Cobalt Energy\u2019s Heidelberg field interest\" data-tweet=\"$WTI $WTI $CIE - W&amp;T Offshore to buy Cobalt Energy\u2019s Heidelberg field interest https://seekingalpha.com/news/3338391-w-and-t-offshore-to-buy-cobalt-energy-s-heidelberg-field-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3338391-w-and-t-offshore-to-buy-cobalt-energy-s-heidelberg-field-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338390\" data-ts=\"1520872315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNSR\" target=\"_blank\">FNSR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338390-analysts-challenges-for-finisar-in-lumentum-oclaro-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts: Challenges for Finisar in Lumentum-Oclaro deal</a></h4><ul>   <li>Today's <a href=\"https://seekingalpha.com/news/3338226-optical-deal-lumentum-buying-oclaro-1_8b\" target=\"_blank\">news of a deal</a> between Lumentum (<a href=\"http://seekingalpha.com/symbol/LITE\" target=\"_blank\">LITE</a> <font color='green'>+6.9%</font>) and Oclaro (<a href=\"http://seekingalpha.com/symbol/OCLR\" target=\"_blank\">OCLR</a> <font color='green'>+27%</font>) has nearly all optical-equipment makers on a roll, though analysts see some scaling challenge ahead for Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>).</li>    <li>Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) is <font color='green'>up 6.5%</font>; NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>) <font color='green'>+6.7%</font>; Emcore (NASDAQ:<a href='https://seekingalpha.com/symbol/EMKR' title='EMCORE Corporation'>EMKR</a>) <font color='green'>+3.2%</font>; Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a>) <font color='green'>+6.3%</font>.</li>    <li>Finisar (<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>) is <font color='green'>+4.5%</font> though the Oclaro deal's a likely negative, says B. Riley FBR, since Finisar was the most likely buyer for Oclaro as it could helped scale up the datacom business.</li><li>And Fabrinet (<a href=\"http://seekingalpha.com/symbol/FN\" target=\"_blank\">FN</a> <font color='red'>-3.4%</font>) will probably have to make price concessions after a combined Lumentum/Oclaro, analyst Dave Kang says. (h/t Bloomberg)</li>    <li>Meanwhile, Finisar needs to keep looking, and Applied Opto could be a good target due in part to higher gross margins, D.A. Davidson says. Acacia or NeoPhotonics are also possibilities.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338390\" data-linked=\"Analysts: Challenges for Finisar in Lumentum-Oclaro deal\" data-tweet=\"$FNSR $FNSR $AAOI - Analysts: Challenges for Finisar in Lumentum-Oclaro deal https://seekingalpha.com/news/3338390-analysts-challenges-for-finisar-in-lumentum-oclaro-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3338390-analysts-challenges-for-finisar-in-lumentum-oclaro-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338385\" data-ts=\"1520871170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOLD\" target=\"_blank\">GOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338385-barrick-gold-upgraded-newmont-mining-downgraded-rbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barrick Gold upgraded, Newmont Mining downgraded at RBC</a></h4><ul>     <li>Barrick Gold (ABX <font color='green'>+2%</font>) jumps after RBC Capital <a href=\"https://www.barrons.com/articles/buy-barrick-gold-sell-newmont-mining-1520867786\" target=\"_blank\">upgrades</a> shares to Outperform from Sector Perform with a $16 price target, arguing ABX's cost guidance and declining production profile already are priced in, and the current valuation puts the stock at an attractive entry point.</li>     <li>Meanwhile, RBC downgrades Newmont Mining (<a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a> <font color='red'>-0.1%</font>) to Underperform from Sector Perform and trims its price target to $43 from $45, saying it is time to take profits following the recent rally even while NEM has executed well on its business plan and has solid fundamentals.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338385\" data-linked=\"Barrick Gold upgraded, Newmont Mining downgraded at RBC\" data-tweet=\"$GOLD $GOLD $NEM - Barrick Gold upgraded, Newmont Mining downgraded at RBC https://seekingalpha.com/news/3338385-barrick-gold-upgraded-newmont-mining-downgraded-rbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3338385-barrick-gold-upgraded-newmont-mining-downgraded-rbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338384\" data-ts=\"1520871010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REGN\" target=\"_blank\">REGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338384-sell-siders-weigh-in-on-praluent-price-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-siders weigh in on Praluent price cut</a></h4><ul><li>Sell-side analysts comment on Regeneron Pharmaceuticals (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='green'>+0.7%</font>) and Sanofi's (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='green'>+0.5%</font>) announced price reduction on cholesterol med Praluent (alirocumab).</li><li>Baird's Brian Skorney (OUTPERFORM/$408 on REGN): Conclusion from ICER (Institute for Clinical and Economic Review) that Praluent would be cost effective at $2.0K - 3.4K for all patients and $4.5K - 8.0K for high-risk patients with elevated bad cholesterol would be a 43 - 68% discount and may trigger a price war. He says Amgen (<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='red'>-0.9%</font>) would have to cut the price on Repatha (evolocumab) even more to grab market share. Current consensus on Praluent and Repatha together is $1.2B - 2.7B in 2022 but forecasts for Praluent could \"flip-flop\" in the coming weeks.</li><li>Raymond James' Laura Chico (OUTPERFORM/$399): \"Somewhat \"cautious\" on Praluent's trajectory. Management sees population of 300K - 400K high-risk patients in U.S., only 38K being treated at present.</li><li>Barclays' Geoff Meacham (UNDERWEIGHT/$315): Revised commercial strategy \"unlikely to improve sales and growth trajectory\" since payers will restrict access considering the pricing differential versus statins.</li><li>BMO's Matthew Luchini (MARKET PERFORM/$398): Study data largely in line with expectations, but sees focus shifting to price and patient access. Change in sales trajectory contingent on revised AHA/ACC guidelines and improved payer access.</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color='red'>-0.3%</font>)(<a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a> <font color='green'>+3.4%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3338384\" data-linked=\"Sell-siders weigh in on Praluent price cut\" data-tweet=\"$REGN $REGN $SNY - Sell-siders weigh in on Praluent price cut https://seekingalpha.com/news/3338384-sell-siders-weigh-in-on-praluent-price-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3338384-sell-siders-weigh-in-on-praluent-price-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338380\" data-ts=\"1520870600\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRKR\" target=\"_blank\">PRKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338380-parkervisionplus-22_5-on-favorable-venue-ruling-for-patent-fight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ParkerVision +22.5% on favorable venue ruling for patent fight</a></h4><ul><li>        ParkerVision (<a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a>)<font color='green'>&nbsp;jumps 22.5%</font>&nbsp;to nearly a dollar on news that the company <a href=\"https://seekingalpha.com/pr/17098751-parkervision-receives-favorable-venue-ruling-patent-infringement-case-qualcomm-apple\" target=\"_blank\">received a favorable venue ruling</a> in its patent infringement case against Qualcomm and Apple.</li><li>               Judge Brian J. Davis of the Federal Court in the Middle District of Florida denied Qualcomm&rsquo;s attempt to transfer the matter to California and Apple&rsquo;s motion to dismiss for improper venue. &nbsp;&nbsp;</li><li>               ParkerVision CEO Jeffery Parker: &ldquo;We are pleased that&nbsp;Judge Davis&nbsp;has agreed with ParkerVision that the&nbsp;Middle District&nbsp;of&nbsp;Florida&nbsp;is the proper venue for this case.&nbsp; We anticipate the case can now move expeditiously toward a Markman hearing, and we look forward to the court&rsquo;s guidance on claim construction.&rdquo;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338380\" data-linked=\"ParkerVision +22.5% on favorable venue ruling for patent fight\" data-tweet=\"$PRKR - ParkerVision +22.5% on favorable venue ruling for patent fight https://seekingalpha.com/news/3338380-parkervisionplus-22_5-on-favorable-venue-ruling-for-patent-fight?source=tweet\" data-url=\"https://seekingalpha.com/news/3338380-parkervisionplus-22_5-on-favorable-venue-ruling-for-patent-fight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338379\" data-ts=\"1520870516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PYX\" target=\"_blank\">PYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338379-consumer-top-gainers-losers-of-12-00-pm-3-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm (3/12/2018)</a></h4><ul>     <li><b>Gainers:</b> AOI <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/DLA' title='Delta Apparel, Inc'>DLA</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/MTEX' title='Mannatech, Incorporated'>MTEX</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BRID' title='Bridgford Foods Corporation'>BRID</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/AMWD' title='American Woodmark Corporation'>AMWD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/DECK' title='Deckers Outdoor Corporation'>DECK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/DORM' title='Dorman Products, Inc.'>DORM</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338379\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm (3/12/2018)\" data-tweet=\"$PYX $PYX $DLA - Consumer - Top Gainers / Losers as of 12:00 pm (3/12/2018) https://seekingalpha.com/news/3338379-consumer-top-gainers-losers-of-12-00-pm-3-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3338379-consumer-top-gainers-losers-of-12-00-pm-3-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338376\" data-ts=\"1520869943\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338376-apple-acquires-magazine-subscription-app-texture\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple acquires magazine subscription app Texture</a></h4><ul><li>        Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) <a href=\"https://beta.techcrunch.com/2018/03/12/apple-acquires-digital-newsstand-texture-as-it-doubles-down-on-content-from-trusted-sources/\" target=\"_blank\">acquires</a> digital magazine subscription app Texture for undisclosed terms.</li><li>               Texture charges $9.99/month to give readers access to 200 magazines.&nbsp;</li><li>               Apple&rsquo;s Eddy Cue confirms the buy in a statement (via TechCrunch): &ldquo;We&rsquo;re excited Texture will join Apple, along with an impressive catalog of magazines from many&nbsp;of the world&rsquo;s leading publishers. We are committed to quality journalism from trusted sources and allowing&nbsp;magazines to keep producing beautifully designed and engaging stories for users.&rdquo;&nbsp;</li><li>               Apple is taking the full company including employees and Apple didn&rsquo;t indicate any plans to change Texture after the deal closes.&nbsp;</li><li>               Apple shares are&nbsp;<font color='green'>up 0.9%</font>&nbsp;to $181.68.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338376\" data-linked=\"Apple acquires magazine subscription app Texture\" data-tweet=\"$AAPL - Apple acquires magazine subscription app Texture https://seekingalpha.com/news/3338376-apple-acquires-magazine-subscription-app-texture?source=tweet\" data-url=\"https://seekingalpha.com/news/3338376-apple-acquires-magazine-subscription-app-texture\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338375\" data-ts=\"1520869715\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CENX\" target=\"_blank\">CENX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338375-century-aluminum-upgraded-bmo-tariffs-to-lift-volumes-and-premiums\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Century Aluminum upgraded at BMO, as tariffs to lift volumes and premiums</a></h4><ul>     <li>Century Aluminum (<a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='green'>+4.9%</font>) shoots higher after BMO&nbsp;Capital <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/03/11342930/century-aluminum-upgraded-bmo-analyst-says-tariffs-will\" target=\"_blank\">upgrades</a> shares to Outperform from Market Perform with a $28 price target, raised from $20, saying the Trump administration's steel and aluminum tariffs will lead to higher Midwest premiums.</li>     <li>BMO believes CENX shares do not reflect the valuation implications of higher company-specific volumes and the firm's views of higher-for-longer Midwest premiums, estimating a \"clearing Midwest premium\" of ~$0.20/lb. vs. the spot price of $0.17/lb. and historical price of $0.08.</li>     <li>BMO projects CENX annual EBITDA of more than $450M once volumes and premiums reset, with an incremental EBITDA opportunity from the higher Midwest premium of $50M-$60M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338375\" data-linked=\"Century Aluminum upgraded at BMO, as tariffs to lift volumes and premiums\" data-tweet=\"$CENX - Century Aluminum upgraded at BMO, as tariffs to lift volumes and premiums https://seekingalpha.com/news/3338375-century-aluminum-upgraded-bmo-tariffs-to-lift-volumes-and-premiums?source=tweet\" data-url=\"https://seekingalpha.com/news/3338375-century-aluminum-upgraded-bmo-tariffs-to-lift-volumes-and-premiums\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338371\" data-ts=\"1520868143\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338371-amazon-roundup-alexa-goes-to-work-amazon-strengthens-vietnam-push\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon roundup: Alexa goes to work, Amazon strengthens Vietnam push</a></h4><ul><li>        Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) CTO Werner Vogels <a href=\"https://www.axios.com/scoop-amazon-is-introduc-1520787349-254bffea-bf44-4cc2-8f2b-8aa046338e68.html\" target=\"_blank\">tells Axios</a> that Alexa will soon come to a variety of business settings to help the voice assistant learn different types of conversations.</li><li>               The previously announced Alexa for Business will include several parts including integrating the voice assistant into enterprise software and customizable skills.&nbsp;</li><li>               Early Alexa for Business partners include Concur and Salesforce on the tech side and WeWork, CapitalOne, and Wynn hotels among the participating businesses.&nbsp;</li><li>                  Vogels insists that Alexa for Business doesn&rsquo;t interfere with the partnership with Microsoft&rsquo;s Cortana, even though it steps into Microsoft&rsquo;s enterprise territory.    </li><li>               In other Amazon news, the <a href=\"https://asia.nikkei.com/Business/Companies/Amazon-to-enter-Vietnam-to-take-on-Alibaba\" target=\"_blank\">company teams up</a> with Vietnam E-commerce Association &#40;VECOM&#41; for a stronger push into the Vietnamese market.&nbsp;</li><li>               Amazon is expected to release its official plans for the region on March 14 at the Vietnam Online Business Forum, but partnering with VECOM will give Amazon better access to products and local small and medium-sized businesses to list on the platform.&nbsp;</li><li>               Amazon currently lags behind Alibaba, which got a head-start in the region.&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 1.1%</font>&nbsp;to $1,595.86.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338371\" data-linked=\"Amazon roundup: Alexa goes to work, Amazon strengthens Vietnam push\" data-tweet=\"$AMZN - Amazon roundup: Alexa goes to work, Amazon strengthens Vietnam push https://seekingalpha.com/news/3338371-amazon-roundup-alexa-goes-to-work-amazon-strengthens-vietnam-push?source=tweet\" data-url=\"https://seekingalpha.com/news/3338371-amazon-roundup-alexa-goes-to-work-amazon-strengthens-vietnam-push\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338366\" data-ts=\"1520867709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COR\" target=\"_blank\">COR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338366-coresite-realtyplus-3_7-keybanc-lifts-to-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CoreSite Realty +3.7% as KeyBanc lifts to Overweight</a></h4><ul>   <li>CoreSite Realty (NYSE:<a href='https://seekingalpha.com/symbol/COR' title='CoreSite Realty Corporation'>COR</a>) is <font color='green'>up 3.7%</font> and at its highest point in over a month after an upgrade to Overweight by KeyBanc.</li>    <li>\"We anticipate COR will <a href=\"https://www.streetinsider.com/Analyst+Comments/KeyBanc+Upgrades+CoreSite+Realty+%28COR%29+to+Overweight/13929433.html\" target=\"_blank\">deliver steady, premium AFFO growth</a> driven by continued lease signings and investment in new development,\" analyst Jordan Sadler writes.</li>    <li>\"While COR&rsquo;s 2018 AFFO growth is poised to slow from the heady 15-20% per year pace achieved over the last several years, the 'relaunch' management described as taking place in 2018 should reposition the company to once again deliver mid-teens growth.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338366\" data-linked=\"CoreSite Realty +3.7% as KeyBanc lifts to Overweight\" data-tweet=\"$COR - CoreSite Realty +3.7% as KeyBanc lifts to Overweight https://seekingalpha.com/news/3338366-coresite-realtyplus-3_7-keybanc-lifts-to-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3338366-coresite-realtyplus-3_7-keybanc-lifts-to-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338365\" data-ts=\"1520867193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DKS\" target=\"_blank\">DKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338365-sporting-goods-sector-strong-in-front-of-dicks-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sporting goods sector strong in front of Dick&#39;s earnings</a></h4><ul> <li>The sporting good sector is in rally mode ahead of tomorrow earnings report from Dick's Sporting Goods (NYSE:<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a>).</li> <li>Dick's is&nbsp;<font color='green'>up 4.9%</font>, while Big 5 Sporting Goods BGFV is&nbsp;<font color='green'>4.1% highe</font>r and Hibbett Sports (NASDAQ:<a href='https://seekingalpha.com/symbol/HIBB' title='Hibbett Sports, Inc.'>HIBB</a>) is showing a&nbsp;<font color='green'>2.6% gain</font>.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3338365\" data-linked=\"Sporting goods sector strong in front of Dick&#39;s earnings\" data-tweet=\"$DKS $DKS $HIBB - Sporting goods sector strong in front of Dick&#39;s earnings https://seekingalpha.com/news/3338365-sporting-goods-sector-strong-in-front-of-dicks-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3338365-sporting-goods-sector-strong-in-front-of-dicks-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338364\" data-ts=\"1520867144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FBR\" target=\"_blank\">FBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338364-report-fibria-celulose-receives-12_3b-takeover-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Fibria Celulose receives $12.3B takeover offer</a></h4><ul>     <li>Fibria Celulose (<a href='https://seekingalpha.com/symbol/FBR' title='Fibria Celulose S.A.'>FBR</a> <font color='green'>+3.4%</font>) is higher after reportedly <a href=\"https://www.reuters.com/article/us-fibria-m-a-paper-excellence/paper-excellence-delivers-formal-bid-for-brazilian-pulp-producer-fibria-sources-idUSKCN1GO1HU\" target=\"_blank\">receiving a $12.3B takeover offer</a> (40B Brazilian reais) from Netherlands-based wood pulp producer Paper Excellence.</li>     <li>Paper Excellence decided to bid after reports of FBR negotiations with rivals, according to <em>Valor Economico</em>.</li>     <li>Paper Excellence, which also owns Indonesia&rsquo;s Asia Pulp &amp; Paper, acquired Eldorado Brasil Celulose last year for $4.7B; FBR and Eldorado have units in the same city, Tr&ecirc;s Lagoas.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338364\" data-linked=\"Report: Fibria Celulose receives $12.3B takeover offer\" data-tweet=\"$FBR - Report: Fibria Celulose receives $12.3B takeover offer https://seekingalpha.com/news/3338364-report-fibria-celulose-receives-12_3b-takeover-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3338364-report-fibria-celulose-receives-12_3b-takeover-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338340\" data-ts=\"1520866966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMP\" target=\"_blank\">IMMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338340-healthcare-top-5-gainers-losers-of-11-00-3-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am (3/12/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IMMP' title='Immutep Limited ADR'>IMMP</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/INNT' title='Innovate Biopharmaceuticals, Inc.'>INNT</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/JNP' title='Juniper Pharmaceuticals, Inc.'>JNP</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CGNT' title='Cogentix Medical, Inc.'>CGNT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/IFRX' title='InflaRx N.V.'>IFRX</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a> <font color='red'>-80%</font>. <a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='red'>-74%</font>. <a href='https://seekingalpha.com/symbol/VYGR' title='Voyager Therapeutics'>VYGR</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a> <font color='red'>-10%</font>. EBIO <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338340\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am (3/12/2018)\" data-tweet=\"$IMMP $IMMP $INNT - Healthcare - Top 5 Gainers / Losers as of 11:00 am (3/12/2018) https://seekingalpha.com/news/3338340-healthcare-top-5-gainers-losers-of-11-00-3-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3338340-healthcare-top-5-gainers-losers-of-11-00-3-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338357\" data-ts=\"1520866578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338357-competition-fears-around-blue-apron\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Competition fears around Blue Apron</a></h4><ul> <li>Blue Apron (<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a> <font color='red'>-5.9%</font>) is lower again as investors size up the company's new competition in the meal kit market.</li> <li>Last week, Weight Watchers (<a href='https://seekingalpha.com/symbol/WTW' title='Weight Watchers International, Inc.'>WTW</a> <font color='green'>+2.6%</font>) announced the upcoming <a href=\"https://seekingalpha.com/pr/17096463-weight-watchers-launches-ww-healthy-kitchen-inspire-healthier-habits-home-go\" target=\"_blank\">launch</a> of WWW Healthy Kitchen quick-prep meal kits. Earlier this month, it was Walmart casting a shadow over Blue Apron.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3336378-blue-apron-slumps-walmart-enters-online-meal-kit-game\" target=\"_blank\">Blue Apron slumps after Walmart enters online meal kit game</a> (March 5)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3338357\" data-linked=\"Competition fears around Blue Apron\" data-tweet=\"$APRN $APRN $WW - Competition fears around Blue Apron https://seekingalpha.com/news/3338357-competition-fears-around-blue-apron?source=tweet\" data-url=\"https://seekingalpha.com/news/3338357-competition-fears-around-blue-apron\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338354\" data-ts=\"1520866308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTR\" target=\"_blank\">NTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338354-potash-production-said-unaffected-after-accident-belarus-mine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Potash production said unaffected after accident at Belarus mine</a></h4><ul>     <li>Potash producers Nutrien (<a href='https://seekingalpha.com/symbol/NTR' title='Nutrien Ltd.'>NTR</a> <font color='red'>-1.5%</font>), Mosaic (<a href='https://seekingalpha.com/symbol/MOS' title='The Mosaic Company'>MOS</a> <font color='red'>-0.8%</font>) and Intrepid Potash (<a href='https://seekingalpha.com/symbol/IPI' title='Intrepid Potash, Inc.'>IPI</a> <font color='red'>-1%</font>) slump after <a href=\"https://seekingalpha.com/news/3338118-potash-stocks-jump-reports-belarus-mine-collapse\" target=\"_blank\">Friday's headlines</a> of a Belaruskali potash mine collapse turn out to be a <a href=\"https://www.streetinsider.com/Analyst+Comments/Scotiabank+Sees+Pullback+in+Potash+Names+as+Belaruskali+was+a+Minor+Event+%28NTR%29+%28MOS%29/13931158.html\" target=\"_blank\">minor event</a>.</li>     <li><a href=\"https://www.reuters.com/article/us-belarus-potash-accident/belaruskali-potash-production-unaffected-after-mine-accident-idUSKBN1GM07S\" target=\"_blank\">Potash production was unaffected</a> at the Belarus miner, the world&rsquo;s top exporter of the fertilizer ingredient, following an accident at the mine, deputy chief executive Anatoly Makhlai told Reuters.</li>     <li>Two miners were missing after the accident, which reportedly involved a rock slide an a burst of methane.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338354\" data-linked=\"Potash production said unaffected after accident at Belarus mine\" data-tweet=\"$NTR $NTR $MOS - Potash production said unaffected after accident at Belarus mine https://seekingalpha.com/news/3338354-potash-production-said-unaffected-after-accident-belarus-mine?source=tweet\" data-url=\"https://seekingalpha.com/news/3338354-potash-production-said-unaffected-after-accident-belarus-mine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338351\" data-ts=\"1520865538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RKDA\" target=\"_blank\">RKDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338351-arcadia-continues-rally-up-65\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arcadia continues rally, up 65%</a></h4><ul><li>Thinly traded nano cap Arcadia Biosciences (<a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='green'>+64.9%</font>) is up on a healthy 24x surge in volume in the first hour of trading. Shares have tripled since last week.</li><li>No particular news accounts for the action, although the company looks like it will need additional capital this year. At the end of <a href=\"https://www.sec.gov/Archives/edgar/data/1469443/000156459017023329/rkda-10q_20170930.htm\" target=\"_blank\">September 2017</a>, it had ~$15.7M in quick assets and operations consumed $11.3M during the first three quarters.</li><li>Q4 results will be <a href=\"https://seekingalpha.com/pr/17095425-arcadia-biosciences-announces-date-fourth-quarter-full-year-2017-financial-results-business\" target=\"_blank\">released </a>on March 20 after the close.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294684-arcadia-bio-licenses-gene-editing-technology-crispr-cas9-mits-broad-institute\" target=\"_blank\">Arcadia Bio licenses gene editing technology CRISPR-Cas9 from MIT's Broad Institute</a> (Sept. 11, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3338351\" data-linked=\"Arcadia continues rally, up 65%\" data-tweet=\"$RKDA - Arcadia continues rally, up 65% https://seekingalpha.com/news/3338351-arcadia-continues-rally-up-65?source=tweet\" data-url=\"https://seekingalpha.com/news/3338351-arcadia-continues-rally-up-65\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338348\" data-ts=\"1520864953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BXC\" target=\"_blank\">BXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338348-bluelinx-soars-after-acquiring-cedar-creek\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlueLinx soars after acquiring Cedar Creek</a></h4><ul> <li>BlueLinx (<a href='https://seekingalpha.com/symbol/BXC' title='BlueLinx Holdings, Inc.'>BXC</a> <font color='green'>+50.4%</font>) announces that it's acquiring&nbsp;building products wholesale distributor Cedar Creek for $413M.</li>   <li>The purchase price will consist of ~$345M in cash and ~$68M as the agreed value of the capital leases.</li><li>The transaction is expected to be completed within 45 days.</li>  <li>The company anticipates that the addition of Cedar Creek will create a leading building products wholesale distributor with one of the largest product offerings in the building products industry, including over 50K&nbsp;branded and private-label SKUs, and a distribution footprint of 70 national locations servicing 40 states.</li><li>$50M of annual cost savings are expected within 18 months.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17098611-bluelinx-enters-strategic-merger-agreement-acquire-cedar-creek\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3338348\" data-linked=\"BlueLinx soars after acquiring Cedar Creek\" data-tweet=\"$BXC - BlueLinx soars after acquiring Cedar Creek https://seekingalpha.com/news/3338348-bluelinx-soars-after-acquiring-cedar-creek?source=tweet\" data-url=\"https://seekingalpha.com/news/3338348-bluelinx-soars-after-acquiring-cedar-creek\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338347\" data-ts=\"1520864768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338347-jefferies-this-upcoming-film-serve-nvidia-amd-catalyst\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies: This upcoming film could serve as Nvidia, AMD catalyst</a></h4><ul><li>        Jefferies <a href=\"https://www.cnbc.com/2018/03/12/nvidia-to-get-a-boost-from-steven-spielbergs-ready-player-one-jefferies.html\" target=\"_blank\">reiterates</a> a Buy rating on Nvidia (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='green'>+3%</font>) with a $300 price target (a 22% upside to Friday&rsquo;s close) and calls Steven Spielberg&rsquo;s upcoming &ldquo;Ready Player One&rdquo; film a potential catalyst. The film hits U.S. theaters on March 29.</li><li>               Characters in the film, which is based on a popular book, escape from a dystopian society using virtual reality. Jefferies thinks this could drive VR headset sales and the headsets involve high-performance chips.&nbsp;</li><li>               But analyst Mark Lipacis does see other benefits to Nvidia: &ldquo;The computing paradigm experiences a tectonic shift every 15 years, and that it is currently in a shift to a 'Parallel Processing &ndash; Internet of Things' model. A lot of the demand for increased compute cycles is becoming parallel in nature, like neural networking, gaming, virtual reality and blockchain/cryptocurrency mining.\"&nbsp;</li><li>               And Nvidia isn&rsquo;t the only company that would benefit from a VR headset boom. Advanced Micro Devices (<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='green'>+0.5%</font>) could become another chip winner. Jefferies has AMD at Buy with a $19 target, a 62% upside.&nbsp;</li><li>               Top VR headset developers: Facebook&rsquo;s (<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a> <font color='red'>-0.3%</font>) Oculus, Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>), Sony (<a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a> <font color='red'>-2.4%</font>), and Samsung (<a href='https://seekingalpha.com/symbol/SSNNF' title='Samsung Electronics Co., Ltd.'>OTC:SSNNF</a>, <a href='https://seekingalpha.com/symbol/SSNLF' title='Samsung Electronics Co., Ltd.'>OTC:SSNLF</a>).&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338347\" data-linked=\"Jefferies: This upcoming film could serve as Nvidia, AMD catalyst\" data-tweet=\"$NVDA $NVDA $AMD - Jefferies: This upcoming film could serve as Nvidia, AMD catalyst https://seekingalpha.com/news/3338347-jefferies-this-upcoming-film-serve-nvidia-amd-catalyst?source=tweet\" data-url=\"https://seekingalpha.com/news/3338347-jefferies-this-upcoming-film-serve-nvidia-amd-catalyst\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338344\" data-ts=\"1520863809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338344-outsized-netflix-rally-questioned-ft\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Outsized Netflix rally questioned by FT</a></h4><ul> <li>An article by Financial Times' <a href=\"https://ftalphaville.ft.com/2018/03/09/1520612404000/This-is-nuts--when-does-Netflix-crash-/\" target=\"_blank\">Dan McCrum</a> asks when does Netflix (<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='red'>-1.3%</font>) crash?</li> <li>McCrum points out that Netflix relies on heavy borrowing to pay for its expenses. \"The debt is rated junk, four notches below investment grade. Were credit markets to close, as they periodically do to weaker borrowers in moments of strife, Nextflix would be shut out, \" he warns.</li> <li>The piece caught the <a href=\"https://twitter.com/CitronResearch/status/973195194018353152\" target=\"_blank\">attention</a> of short-selling firm Citron Research: \"With mkt cap up $17 BIL in a week and short interest. at 10 year low.  Citron thinks the stock can be shorted back to $300.  Content spend unsustainable long term.\"</li><li>Shares of Netflix are up 76% over the last 90 days.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3338344\" data-linked=\"Outsized Netflix rally questioned by FT\" data-tweet=\"$NFLX - Outsized Netflix rally questioned by FT https://seekingalpha.com/news/3338344-outsized-netflix-rally-questioned-ft?source=tweet\" data-url=\"https://seekingalpha.com/news/3338344-outsized-netflix-rally-questioned-ft\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>79&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338343\" data-ts=\"1520863469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338343-adobe-target-raised-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adobe target raised ahead of earnings</a></h4><ul><li>        Stifel maintains a Buy rating on Adobe (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) but raises the price target by $20 to $230 (a 4% upside to last week&rsquo;s close) ahead of Thursday&rsquo;s earnings.</li><li>               Analyst Tom Roderick says industry checks show a &ldquo;fluid IT purchasing environment&rdquo; that will continue to drive even bullish outlooks for cloud-based enterprise platform application leaders.&nbsp;</li><li>               Source: Briefing.com.&nbsp;</li><li>               Adobe shares are&nbsp;<font color='green'>up 0.4%</font>&nbsp;to $221.96.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338343\" data-linked=\"Adobe target raised ahead of earnings\" data-tweet=\"$ADBE - Adobe target raised ahead of earnings https://seekingalpha.com/news/3338343-adobe-target-raised-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3338343-adobe-target-raised-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338338\" data-ts=\"1520863232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGO\" target=\"_blank\">AVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338338-cnbc-cfius-tells-broadcom-violating-order\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNBC: CFIUS tells Broadcom it&#39;s violating order</a></h4><ul>   <li>An \"angry\" Committee on Foreign Investment in the United States has told Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a>) that it's <a href=\"https://www.cnbc.com/video/2018/03/12/appears-cfius-not-happy-with-broadcom-says-cnbcs-david-faber.html\" target=\"_blank\">violated last week's interim order</a> regarding its deal for Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>), CNBC's David Faber says.</li>    <li>Faber said he's seen a copy of the letter to Broadcom, which notes violations on three counts from a \"series of actions.\"</li>    <li>Faber relates that CFIUS says concerns about national security \"have been confirmed\" and in the absence of more information, it plans to take further action, including referring the deal to the president.</li>    <li>A meeting is set for today between Broadcom and CFIUS, he says.</li>    <li>Broadcom is <font color='green'>up 3.1%</font> currently; <a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a> is back to the flat line.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338231-broadcom-moves-redomiciling-hits-back-cfius\" target=\"_blank\">Broadcom moves up redomiciling, hits back at CFIUS</a> (Mar. 12 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338164-reuters-cfius-demands-notice-broadcom-move-redomicile\" target=\"_blank\">Reuters: CFIUS demands notice on Broadcom move to redomicile</a> (Mar. 09 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338153-wsj-intel-considers-deals-including-broadcom-acquisition-avgo-plus-6-percent-updated\" target=\"_blank\">WSJ: Intel considers deals including Broadcom acquisition; AVGO +6% (updated)</a> (Mar. 09 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338338\" data-linked=\"CNBC: CFIUS tells Broadcom it&#39;s violating order\" data-tweet=\"$AVGO $AVGO $QCOM - CNBC: CFIUS tells Broadcom it&#39;s violating order https://seekingalpha.com/news/3338338-cnbc-cfius-tells-broadcom-violating-order?source=tweet\" data-url=\"https://seekingalpha.com/news/3338338-cnbc-cfius-tells-broadcom-violating-order\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>169&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338337\" data-ts=\"1520863113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DECK\" target=\"_blank\">DECK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338337-deckers-lower-after-marcato-exit-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deckers lower after Marcato exit, downgrade</a></h4><ul> <li>Activist firm Marcato Capital Management discloses in a SEC filing that it exited its position in Deckers Outdoor (<a href='https://seekingalpha.com/symbol/DECK' title='Deckers Outdoor Corporation'>DECK</a> <font color='red'>-6.7%</font>).</li> <li>Marcato held a position of 8.5% in the retailer at the beginning of the year.</li> <li><a href=\"https://seekingalpha.com/filing/3931551\" target=\"_blank\">SEC Form 13D </a></li> <li>Previously: <a href=\"https://seekingalpha.com/news/3338266-pivotal-cools-deckers-outdoor\" target=\"_blank\">Pivotal cools on Deckers Outdoor</a> (March 12)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338337\" data-linked=\"Deckers lower after Marcato exit, downgrade\" data-tweet=\"$DECK - Deckers lower after Marcato exit, downgrade https://seekingalpha.com/news/3338337-deckers-lower-after-marcato-exit-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3338337-deckers-lower-after-marcato-exit-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338328\" data-ts=\"1520862220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FN\" target=\"_blank\">FN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338328-fabrinetminus-3_6-northland-notes-customer-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fabrinet -3.6% as Northland notes customer merger</a></h4><ul>   <li>After moving higher premarket, Fabrinet (<a href=\"http://seekingalpha.com/symbol/FN\" target=\"_blank\">FN</a> <font color='red'>-3.6%</font>) has pulled back in the wake of some optical networking consolidation by way of a <a href=\"https://seekingalpha.com/news/3338226-optical-deal-lumentum-buying-oclaro-1_8b\" target=\"_blank\">Lumentum-Oclaro deal</a>.</li>    <li>Northland says Fabrinet could see a pullback of some 10%, with a negative coming from the combination of its two biggest customers. (h/t <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable calls</a>)</li>    <li>Fabrinet is <font color='green'>up 15.3%</font> YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338328\" data-linked=\"Fabrinet -3.6% as Northland notes customer merger\" data-tweet=\"$FN - Fabrinet -3.6% as Northland notes customer merger https://seekingalpha.com/news/3338328-fabrinetminus-3_6-northland-notes-customer-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3338328-fabrinetminus-3_6-northland-notes-customer-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338322\" data-ts=\"1520861915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCB\" target=\"_blank\">MCB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338322-bitcoin-bank-replaces-cfo-shares-off-nearly-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The &#39;Bitcoin Bank&#39; replaces its CFO; shares off nearly 3%</a></h4><ul><li>Metropolitan Bank (NYSE:<a href='https://seekingalpha.com/symbol/MCB' title='Metropolitan Bank Holding Corp.'>MCB</a>) CFO Sangeeta Kishore resigned last week, according to a regulatory filing released Friday evening.</li><li>She's been replaced by current COO Gerard Perri.</li><li>The bank also named Daniel Wong as Principal Accounting Officer for SEC reporting purposes.</li><li>Shares are&nbsp;<font color='red'>down 2.9%</font>&nbsp;in early action.</li><li>Source: <a href=\"https://seekingalpha.com/filing/3930970\" target=\"_blank\">SEC Form 8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3338322\" data-linked=\"The &#39;Bitcoin Bank&#39; replaces its CFO; shares off nearly 3%\" data-tweet=\"$MCB - The &#39;Bitcoin Bank&#39; replaces its CFO; shares off nearly 3% https://seekingalpha.com/news/3338322-bitcoin-bank-replaces-cfo-shares-off-nearly-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3338322-bitcoin-bank-replaces-cfo-shares-off-nearly-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338320\" data-ts=\"1520861795\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMW\" target=\"_blank\">VMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338320-vmware-investor-calls-potential-dell-merger-terrible-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VMware investor calls potential Dell merger a &quot;terrible deal&quot;</a></h4><ul><li>           VMware (<a href='https://seekingalpha.com/symbol/VMW' title='VMware, Inc.'>VMW</a>) shareholder Jericho Capital <a href=\"https://www.bloomberg.com/news/articles/2018-03-12/vmware-shareholder-slams-terrible-dell-technologies-deal-talks\" target=\"_blank\">sends a letter</a> to the company calling the potential reverse merger with Dell (DVMT <font color='green'>+0.1%</font>) a &ldquo;terrible deal.&rdquo; </li><li> Jericho holds about a 1.8% stake, which puts it among the top 15 VMware shareholders. </li><li> Key quote from Jericho managing member Josh Resnick: &ldquo;Even the most casual observer can see that VMW gains nothing by saddling the company&rsquo;s faster growth, net cash, highly strategic software business with the dead weight of Dell&rsquo;s slower growth, heavily debt-laden, legacy hardware-dependent entity.&rdquo; </li><li> Resnick says VMware would be better off pursuing deals with other companies and lists potential acquisition targets including Red Hat (<a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a> <font color='green'>+0.1%</font>), Palo Alto Networks (<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a> <font color='green'>+0.3%</font>), and Splunk (<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>).&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3338320\" data-linked=\"VMware investor calls potential Dell merger a &quot;terrible deal&quot;\" data-tweet=\"$VMW $VMW $DELL - VMware investor calls potential Dell merger a &quot;terrible deal&quot; https://seekingalpha.com/news/3338320-vmware-investor-calls-potential-dell-merger-terrible-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3338320-vmware-investor-calls-potential-dell-merger-terrible-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338315\" data-ts=\"1520861384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHTR\" target=\"_blank\">CHTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338315-charterplus-1_5-on-new-reports-of-softbank-buildup\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Charter +1.5% on new reports of SoftBank buildup</a></h4><ul>   <li>Charter Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a>) is <font color='green'>up 1.5%</font> premarket after reports that SoftBank (<a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a>) has quietly built a stake of nearly 5% with an eye to a $100B merger with Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>).</li>    <li>The <a href=\"https://www.thetimes.co.uk/article/intel-mulls-100bn-bid-for-rival-dlwm0n9g7\" target=\"_blank\"><i>Times of London</i></a> cited Betaville's Ben Harrington on the stake buildup.</li>    <li><a href=\"https://seekingalpha.com/news/3308521-charter-jumps-new-report-softbank-interest\" target=\"_blank\">Charter had jumped in November</a> on similar speculation about such a deal, where Charter would have been acquired at $540/share in cash and stock. Shares closed Friday at $347.59.</li>    <li>Sprint is <font color='green'>up 0.4%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338315\" data-linked=\"Charter +1.5% on new reports of SoftBank buildup\" data-tweet=\"$CHTR $CHTR $SFTBY - Charter +1.5% on new reports of SoftBank buildup https://seekingalpha.com/news/3338315-charterplus-1_5-on-new-reports-of-softbank-buildup?source=tweet\" data-url=\"https://seekingalpha.com/news/3338315-charterplus-1_5-on-new-reports-of-softbank-buildup\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338312\" data-ts=\"1520861099\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADM\" target=\"_blank\">ADM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338312-goldman-sachs-sees-upside-for-archer-daniels-midland\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs sees upside for Archer Daniels Midland</a></h4><ul> <li>Goldman Sachs upgrades Archer Daniels Midland (NYSE:<a href='https://seekingalpha.com/symbol/ADM' title='Archer Daniels Midland Co.'>ADM</a>) to a Buy rating due to the \"substantial tightening in the global soybean crush markets following a drought in Argentina.</li> <li>Analyst Adam Samuelson raises his estimates on Ag Services, Oilseeds and Corn Processing and takes the GS price target on Archer Daniels up to $50 (Street high).</li> <li>Shares of ADM are&nbsp;<font color='green'>up 1.0%</font>&nbsp;in premarket trading to $43.72 vs. a 52-week trading range of $38.59 to $46.39.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3338312\" data-linked=\"Goldman Sachs sees upside for Archer Daniels Midland\" data-tweet=\"$ADM - Goldman Sachs sees upside for Archer Daniels Midland https://seekingalpha.com/news/3338312-goldman-sachs-sees-upside-for-archer-daniels-midland?source=tweet\" data-url=\"https://seekingalpha.com/news/3338312-goldman-sachs-sees-upside-for-archer-daniels-midland\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338307\" data-ts=\"1520860704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCLR\" target=\"_blank\">OCLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338307-premarket-gainers-of-9-05-03-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (03/12/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='green'>+25%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3338226-optical-deal-lumentum-buying-oclaro-1_8b\" target=\"_blank\">acquired</a> by Lumentum (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>).</li>     <li><a href='https://seekingalpha.com/symbol/KANG' title='iKang Healthcare Group, Inc.'>KANG</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17098844-ikang-announces-receipt-acquisition-proposal-yunfeng-capital-alibaba\" target=\"_blank\">acquisition</a> proposal from Yunfeng Capital and Alibaba Investment.</li>     <li><a href='https://seekingalpha.com/symbol/QD' title='Qudian, Inc.'>QD</a> <font color='green'>+8%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3338189-qudian-misses-0_01-misses-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a> <font color='green'>+8%</font>&nbsp;as new <a href=\"https://seekingalpha.com/news/3338284-new-bitcoin-sentiment-tracker-reuters-coming\" target=\"_blank\">bitcoin</a>&nbsp;sentiment tracker from Reuters is coming.</li>     <li><a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='green'>+7%</font>&nbsp;on Japanese patent&nbsp;<a href=\"https://seekingalpha.com/news/3338277-lightbridge-wins-japanese-patent-approval-metallic-fuel-design\" target=\"_blank\">approval</a>&nbsp;for metallic fuel design.</li>     <li><a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a> <font color='green'>+7%</font>&nbsp;as <a href=\"https://seekingalpha.com/news/3338294-optical-names-move-oclaro-sale\" target=\"_blank\">sector tracks</a> higher on Oclaro M&amp;A deal.</li>     <li><a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a> <font color='green'>+6%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3338281-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a>&nbsp;analyst action.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3338307\" data-linked=\"Premarket Gainers as of 9:05 am (03/12/2018)\" data-tweet=\"$OCLR $OCLR $LITE - Premarket Gainers as of 9:05 am (03/12/2018) https://seekingalpha.com/news/3338307-premarket-gainers-of-9-05-03-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3338307-premarket-gainers-of-9-05-03-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338305\" data-ts=\"1520860268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANTH\" target=\"_blank\">ANTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338305-premarket-losers-of-9-05-3-12-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (3/12/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a>&nbsp;<font color='red'>-84%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3338268-anthera-terminate-development-sollpura-failed-late-stage-study\" target=\"_blank\">terminating</a> development of Sollpura after failed late-stage study.</li><li><a href='https://seekingalpha.com/symbol/OREX' title='Orexigen Therapeutics, Inc.'>OREX</a>&nbsp;<font color='red'>-68%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3338295-orexigen-therapeutics-plans-near-term-sale-using-structured-process\" target=\"_blank\">announcing</a> plans for near-term sale using structured process.</li><li><a href='https://seekingalpha.com/symbol/SVRA' title='Savara Inc.'>SVRA</a>&nbsp;<font color='red'>-13%</font>&nbsp;on Aironite <a href=\"https://seekingalpha.com/news/3338218-savaras-aironite-flunks-mid-stage-heart-failure-study-shares-23-percent-premarket\" target=\"_blank\">failing</a> to meet primary endpoint in the Indie Phase 2 clinical study.</li><li><a href='https://seekingalpha.com/symbol/ESPR' title='Esperion Therapeutics'>ESPR</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3338228-eserion-14-percent-premarket-lower-praluent-pricing\" target=\"_blank\">lower</a> Praluent pricing.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3338305\" data-linked=\"Premarket Losers as of 9:05 am (3/12/2018)\" data-tweet=\"$ANTH $ANTH $OREX - Premarket Losers as of 9:05 am (3/12/2018) https://seekingalpha.com/news/3338305-premarket-losers-of-9-05-3-12-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3338305-premarket-losers-of-9-05-3-12-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338304\" data-ts=\"1520860232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KANG\" target=\"_blank\">KANG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338304-chinese-investors-propose-20-ads-takeout-of-ikang-healthcare-shares-up-10-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chinese investors propose $20/ADS takeout of iKang Healthcare; shares up 10% premarket</a></h4><ul><li>Thinly traded iKang Healthcare Group (NASDAQ:<a href='https://seekingalpha.com/symbol/KANG' title='iKang Healthcare Group, Inc.'>KANG</a>) is up&nbsp;<font color='green'>10%&nbsp;</font>premarket on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17098844-ikang-announces-receipt-acquisition-proposal-yunfeng-capital-alibaba\" target=\"_blank\">announcement </a>that it has received a proposal from Yunfeng and Alibaba Investment Limited to acquire the company for $20 per ADS or $40 per share.</li><li>The company says its Special Committee will carefully consider the proposal.</li><li>Friday's close was $17.92.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338304\" data-linked=\"Chinese investors propose $20/ADS takeout of iKang Healthcare; shares up 10% premarket\" data-tweet=\"$KANG - Chinese investors propose $20/ADS takeout of iKang Healthcare; shares up 10% premarket https://seekingalpha.com/news/3338304-chinese-investors-propose-20-ads-takeout-of-ikang-healthcare-shares-up-10-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3338304-chinese-investors-propose-20-ads-takeout-of-ikang-healthcare-shares-up-10-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338302\" data-ts=\"1520859857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYBR\" target=\"_blank\">CYBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338302-cyberark-acquires-cloud-security-assets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CyberArk acquires cloud security assets</a></h4><ul><li>        CyberArk (NASDAQ:<a href='https://seekingalpha.com/symbol/CYBR' title='CyberArk Software Ltd.'>CYBR</a>) <a href=\"https://seekingalpha.com/pr/17098603-cyberark-acquires-vaultive-advance-privileged-account-security-cloud\" target=\"_blank\">acquires</a> certain assets of cloud security provider Vaultive.</li><li>               Terms weren&rsquo;t disclosed and the deal closed today.&nbsp;</li><li>                  CyberArk shares are&nbsp;<font color='green'>up 0.7%</font>&nbsp;premarket to $51.34.    &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3338302\" data-linked=\"CyberArk acquires cloud security assets\" data-tweet=\"$CYBR - CyberArk acquires cloud security assets https://seekingalpha.com/news/3338302-cyberark-acquires-cloud-security-assets?source=tweet\" data-url=\"https://seekingalpha.com/news/3338302-cyberark-acquires-cloud-security-assets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338300\" data-ts=\"1520859824\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGNT\" target=\"_blank\">CGNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338300-laborie-medical-to-acquire-cogentix-medical-for-214m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LABORIE Medical to acquire Cogentix Medical for $214M</a></h4><ul><li>LABORIE Medical Technologies has agreed to <a href=\"https://seekingalpha.com/pr/17098937-laborie-medical-technologies-acquire-cogentix-medical-inc-214-million\" target=\"_blank\">acquire </a>Cogentix Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/CGNT' title='Cogentix Medical, Inc.'>CGNT</a>) for $3.85 per share in cash. The transaction, valued at $214M, should close next quarter.</li><li>CGNT closed Friday at $3.37.</li></ul><div class=\"tiny-share-widget\" data-id=\"3338300\" data-linked=\"LABORIE Medical to acquire Cogentix Medical for $214M\" data-tweet=\"$CGNT - LABORIE Medical to acquire Cogentix Medical for $214M https://seekingalpha.com/news/3338300-laborie-medical-to-acquire-cogentix-medical-for-214m?source=tweet\" data-url=\"https://seekingalpha.com/news/3338300-laborie-medical-to-acquire-cogentix-medical-for-214m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3338286\" data-ts=\"1520859467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDCO\" target=\"_blank\">MDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3338286-medicines-company-up-6-premarket-on-praluent-price-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The Medicines Company up 6% premarket on Praluent price cut</a></h4><ul><li>Regeneron Pharmaceuticals and Sanofi's announced price reduction on PCSK9-inhibitor Praluent (alirocumab), expected to be $7975/year compared to the current $14K wholesale price, appears to be bullish for The Medicines Company (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a>).</li><li>Shares are up&nbsp;<font color='green'>6%</font>&nbsp;premarket, albeit on light volume, as investors perceive improved prospects for MDCO's high cholesterol fighter inclisiran if demand for Praluent spikes after the price cut. Inclisiran lowers bad cholesterol by shutting off PCSK9 synthesis in the liver. Praluent and Amgen's Repatha (evolocumab)&nbsp; are monoclonal antibodies that bind to (inhibit) the PCSK9 enzyme.</li><li>Inclisiran is dosed once or twice per year compared to once per month for Praluent and Repatha.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3324897-medicines-company-continues-inclisiran-stoked-rally-shares-ahead-8-percent\" target=\"_blank\">Medicines Company continues inclisiran-stoked rally, shares ahead 8%</a> (Jan. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3338286\" data-linked=\"The Medicines Company up 6% premarket on Praluent price cut\" data-tweet=\"$MDCO - The Medicines Company up 6% premarket on Praluent price cut https://seekingalpha.com/news/3338286-medicines-company-up-6-premarket-on-praluent-price-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3338286-medicines-company-up-6-premarket-on-praluent-price-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}